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ABSTRACT 
 
SOPHIA SMITH: Quality of Life among non-Hodgkin’s Lymphoma Survivors 
(Under the direction of Sheryl Zimmerman, PhD) 
 
Most of the survivorship research to date has been based on the more common 
types of cancer (e.g., breast, prostate), yet less is known about the quality of life 
(QOL) of survivors of adult non-Hodgkin’s lymphoma (NHL), the sixth most common 
cancer in the US with an individual lifetime risk of 1 in 50. Therefore, the purpose of 
this dissertation is to develop a QOL profile of this heterogeneous group of adult 
NHL survivors. More specifically, the dissertation aims are to: 1) develop prevalence 
estimates and identify risk factors for PTSD symptomatology in 886 survivors of 
adult NHL, with a particular focus on potentially modifiable factors (e.g., social 
support, cognitive appraisals); 2) evaluate whether PTSD and PTG help to explain 
the role of risk factors in relating to QOL in NHL survivors, thereby enhancing our 
understanding of the cancer experience so that processes can be targeted for 
intervention; and 3) compare and contrast the QOL of individuals who reported 
having active NHL to those who were disease-free short-term (2-4 years post-
diagnosis; STS) and long-term (≥5 years post-diagnosis; LTS) survivors. These aims 
are consistent with the “Cancer Survivorship Research and Quality of Life Act of 
2002”, federal legislation introduced by the Lance Armstrong Foundation and a 
bipartisan Congressional group to expand research and quality of life programs for 
cancer survivors. Finally, given the recent advances in cancer therapies with the 
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associated transition of cancer to a chronic illness with alternating periods of disease 
and remission, as is increasingly the case with NHL, this dissertation study also 
provides a window into the diverse needs of cancer survivors in general. Funding for 
this dissertation study was provided by the National Cancer Institute (#R03-CA-
101492), the American Cancer Society Doctoral Training Grant in Oncology Social 
Work (#DSW-0321301-SW), and the University of North Carolina at Chapel Hill 
(University Research Council award). 
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CHAPTER 1 
 
Introduction 
 
  2 
The National Cancer Institute1 now estimates that there are 10.8 million cancer 
survivors in the US, a size equivalent to the population of Los Angeles, CA and 
representing about 3.7 percent of the population. Coinciding with this growing 
population is an increased interest in the quality of life (QOL) of individuals living with 
a cancer diagnosis. Research studies suggest that long-term survivors who were 
diagnosed and treated for one of the more common forms of adult cancer report 
similar QOL to that of the general population,2-5 but many experience specific 
difficulties such as  sexual dysfunction,4,6,7 energy level and fatigue,2,8,9 and post-
traumatic stress disorder (PTSD).10-13 Conversely, a recent focus has emerged on 
the positive outcomes or post-traumatic growth (PTG) associated with the cancer 
experience, such as greater appreciation for life, closer personal relationships, and 
deeper spiritual understanding.7,14,15   
 Most of the above research has been based on breast and prostate cancer 
survivors, yet less is known about the QOL of survivors of adult non-Hodgkin’s 
lymphoma (NHL), the sixth most common cancer in the US with an individual lifetime 
risk of 1 in 50. NHL is a heterogeneous group of cancers of the lymphatic system 
with an overall 5-year survival rate of 50-60%; mortality varies greatly depending on 
the cell type, stage of disease at the time of diagnosis, and treatment. Indolent 
lymphomas generally carry a good prognosis (with a median survival of 10 years) 
but a high rate of relapse, and are usually not curable in advance stages. Treatment 
plans for the indolent forms include periods of watchful waiting, radiation therapy and 
chemotherapy. In contrast, many individuals who convert to or present with 
aggressive forms of NHL can be cured (30-60%) with intensive chemotherapy 
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regimens but the disease has a shorter natural history, with the greatest risk of 
relapse within 2 years of treatment cessation.16 
 The incidence rates of NHL have doubled since the early 1970’s, partly 
because of AIDS-related NHL and improved methods of diagnosis. Over the next 
few years, the increasing average age of the American population together with the 
growing number of medical advances are expected to add to the incidence rates of 
NHL.17 Consequently, and since the number of cancer survivors in the US is rapidly 
increasing, health care teams would benefit from evidence regarding the needs of 
this population so that interventions can be designed to improve their overall 
functioning and QOL. Therefore, the purpose of this dissertation is to develop a QOL 
profile of this heterogeneous group of adult NHL survivors.  
More specifically, the dissertation aims are to: 1) develop prevalence 
estimates and identify risk factors for PTSD symptomatology in 886 survivors of 
adult NHL, with a particular focus on potentially modifiable factors (e.g., social 
support, cognitive appraisals); 2) evaluate whether PTSD and PTG help to explain 
the role of risk factors in relating to QOL in NHL survivors, thereby enhancing our 
understanding of the cancer experience so that processes can be targeted for 
intervention; and 3) compare and contrast the QOL of individuals who reported 
having active NHL to those who were disease-free short-term (2-4 years post-
diagnosis; STS) and long-term (≥5 years post-diagnosis; LTS) survivors. These aims 
are consistent with the “Cancer Survivorship Research and Quality of Life Act of 
2002”, federal legislation introduced by the Lance Armstrong Foundation and a 
bipartisan Congressional group to expand research and quality of life programs for 
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cancer survivors. Finally, given the recent advances in cancer therapies with the 
associated transition of cancer to a chronic illness with alternating periods of disease 
and remission, as is increasingly the case with NHL, this dissertation study also 
provides a window into the diverse needs of cancer survivors in general.  
Funding for this dissertation study was provided by the National Cancer 
Institute (#R03-CA-101492), the American Cancer Society Doctoral Training Grant in 
Oncology Social Work (#DSW-0321301-SW), and the University of North Carolina at 
Chapel Hill (University Research Council award). Approval for all procedures was 
granted by the Institutional Review Boards at the UNC and Duke Schools of 
Medicine. Potential study subjects (≥19 years old, diagnosed with NHL, at least 2 
years post-diagnosis) were identified through the Duke and University of North 
Carolina (UNC) Lineberger Comprehensive Cancer Center Tumor Registries and 
contacted by mail following physician approval. Prospective participants were sent 
an introductory letter signed by their physician, a self-administered questionnaire 
which contained several QOL measures, a $2 bill incentive, and thank-you/reminder 
postcards. Non-respondents were sent replacement mailings and followed up by 
telephone to confirm receipt of the survey packet.  A total of 886 NHL survivors 
participated, representing a response rate of 74%. 
 Each of the three chapters (2-4) included in the dissertation correspond with 
the three aims described above. For example, the purpose of the second chapter, 
entitled “Post-traumatic Stress Outcomes in Non-Hodgkin’s Lymphoma Survivors”, is 
to estimate the prevalence of and identify the risk factors for PTSD symptoms in 
NHL survivors, with a focus on those that are amenable for screening and 
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modifiable. The prevalence (adjusted for survey non-response) for full PTSD in the 
sample was 7.9%, with an additional 9.1% meeting criteria for partial PTSD and 39% 
overall having some level of PTSD symptomatology. Modifiable risk factors that were 
independently associated with PTSD in a multiple linear regression included less 
social support, negative appraisals of life threat and treatment intensity, and more 
employment and insurance issues. Additionally, several demographic characteristics 
(non-Caucasian race, less education, younger age) and clinical or health-related 
factors (active disease, more recent diagnosis, more co-morbidity) were 
independently associated with PTSD. 
The third chapter, entitled “The Mediating Role of Cancer-related Trauma 
Outcomes on Quality of Life”, examines how PTSD and PTG might intervene 
between (i.e., mediate the relationship between) demographic, clinical, health status, 
and psychosocial stressors (i.e., risk factors) and QOL in cancer survivors. Structural 
equation modeling (SEM) was used to evaluate competing models in which risk 
factors were conceptualized as having either direct or indirect (through PTSD and 
PTG) relationships to QOL. The conceptual models used in this analyses and 
throughout the dissertation study are based on the information processing18,19 and 
stress, coping, and adaptation theories.20,21 Information processing helps to explain 
how one’s life schema is disrupted by the cancer experience, and how individuals 
who are able to assimilate or accommodate the life threat into existing schemas are 
more likely to experience positive outcomes, such as PTG. Conversely, negative 
outcomes such as PTSD can be explained by stress, coping and adaptation 
theories, which explain how the stress entailed with a cancer diagnosis and 
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subsequent treatment may overwhelm an individuals ability cope, as the stressors 
are appraised as exceeding one’s resources and endangering well-being. SEM 
results revealed that QOL was best explained by the conceptual model in which the 
relationships of risk factors (e.g., lower social support and education) were partially 
mediated by PTSD and PTG (RMSEA=.072, CFI=.868, TLI=.865). Furthermore, this 
model explained a sizable amount of the variance (82%) in QOL for NHL survivors. 
 The fourth chapter, entitled “Quality of Life among Non-Hodgkin’s Lymphoma 
Survivors”, presents a QOL profile of this heterogeneous group of cancer survivors, 
including a comparison between those who have reported having active disease and 
being in remission or cured (short-term, 2-4 years, STS; long-term, ≥5 years post-
diagnosis, LTS).  As expected, those with active disease were found to have poorer 
QOL than disease-free survivors.  By contrast, no statistically significant differences 
were found in QOL between STS and LTS, and in fact mean differences were no 
greater than 5% on any measure. Given the recent advances in cancer therapies 
with the associated transition of cancer to a chronic illness with alternating periods of 
disease and remission, as is increasingly the case with NHL, this chapter also 
provides a window into the diverse needs of cancer survivors in general.  
  7 
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INTRODUCTION 
 
A growing body of evidence suggests that the experience of being diagnosed 
with and treated for cancer, regardless of age, adversely affects functioning and 
quality of life.  However, less is known about the longer-term effects (two years post-
diagnosis and beyond) of cancer on survivors’ well-being, especially adults with 
other than breast cancer.  Of note, little is known about the needs of individuals 
diagnosed with non-Hodgkin’s lymphoma (NHL), which is the sixth most common 
cancer in the US and has an overall 5-year survival rate of 63%.  
NHL incidence rates have doubled since the early 1970’s, an increase that is 
only partially explained by AIDS-related NHL. The lifetime risk for developing NHL is 
about 1 in 50, with older adults (median age of 66) at highest risk.1 Consequently, 
and since the number of survivors in the US is rapidly increasing due to both medical 
advances that treat other conditions and the aging of the population, healthcare 
teams would benefit from evidence regarding the needs of NHL survivors. If 
indicated, interventions could be provided to improve their well-being.  
 
Cancer-related Traumatic Stress 
Post-traumatic Stress Disorder (PTSD) is a set of symptoms (re-experiencing, 
avoidance, and arousal) following direct exposure to a traumatic stressor where the 
individual is involved in, witnesses, or learns about threatened death or serious 
injury.  Symptoms of PTSD such as re-experiencing distressing events, avoiding 
cancer-related experiences, and physiological arousal have been reported by breast 
cancer survivors, with prevalence estimates ranging from 5-6%2-5.  Unfortunately, 
little data are available regarding PTSD in other adult cancers.  
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A conceptual model for cancer-related PTSD is illustrated in Figure 2.1, in 
which the cancer diagnosis and associated events such as treatment and general 
health status are conceptualized as stressors. Demographic characteristics and 
psychosocial resources relate to the stressors, and these three sets of variables can 
directly or indirectly influence PTSD. This model is based on Lazarus and 
Folkman’s6 stress, appraisal and coping theory, which emphasizes the relationship 
between the person (his/her characteristics) and his/her environment (cancer 
experience).  Of note, cancer-related PTSD differs from more traditional traumas in 
that the intrusions tend to be future-oriented fears such as about recurrence or 
treatment.   The model reflects risk factors identified in previous studies of adult 
cancer survivors, including younger age;7 female gender, negative perceptions of 
treatment intensity;8 lower income;2 less social support and education;3 and less time 
since treatment and advanced disease.4 This paper presents prevalence estimates 
and risk factors for PTSD, with a particular focus on potentially modifiable factors.  
METHODS 
 
Participants and Procedures 
Potential study participants were identified through Tumor Registries at the 
Duke and University of North Carolina at Chapel Hill (UNC) Lineberger 
Comprehensive Cancer Centers. Patients were eligible if they were diagnosed with 
NHL, were at least 19 years at diagnosis, and were at least two years post-
diagnosis, whether or not they had currently active disease. Each patient’s physician 
granted approval before the researchers requested patient participation. Approval for 
all procedures was granted by the Institutional Review Boards at the UNC and Duke 
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University Schools of Medicine. Based on Dillman’s method for mailed surveys,9 
prospective subjects were sent a brief pre-notice letter, a self-administered 
questionnaire with a $2 bill incentive and other study-related materials, and thank-
you/reminder postcards. Non-respondents were sent replacements and later 
telephoned to confirm receipt of the mailed survey packet.  
Measures 
Demographic and Clinical Characteristics 
Self-reported participant demographic information included birthdate, gender, 
race, ethnicity, marital status, income, and education. Details regarding diagnosis 
and treatment were obtained from Tumor Registry databases. Histology was 
categorized as indolent or aggressive based on the updated Revised European 
American Lymphoma/World Health Organization (REAL/WHO) classification 
system.10 
Health Status 
The Self-administered Co-morbidity Questionnaire (SCQ), a 12-item self-report 
version of the Charlson Index, was used to assess other health-related problems.11 
An individual can receive up to 3 points for each of 12 medical conditions (1 point 
each for presence of the problem, current treatment, and functional limitation). 
Selected questions related to healthcare use and secondary cancer status were 
adapted from the Childhood Cancer Survivor Study survey, a large epidemiological 
study of long-term survivors of childhood cancer.12  
Psychosocial 
Perceived availability of social support was assessed using the 20-item Medical 
Outcomes Study-Social Support Survey (MOS-SSS).13 It has been used in various 
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populations, including long-term breast cancer survivors.3,14 The standardized score 
ranges from 20-100 and yielded an α=.97 in this study.  The Appraisal of Life Threat 
and Treatment Intensity Questionnaire (ALTTIQ) assesses the extent to which 
cancer and its treatment are perceived to be life-threatening and intense in the past 
and currently.15 Its six items sum to a score ranging from 6-30 and yielded an α=.80 
in the present study.  Finally, to assess employment and insurance-related situations 
and difficulties, 24 items (possible range 0-24, α=.82) were derived from an 
instrument developed by the Cancer and Leukemia Group B (CALGB) clinical 
research group.16 Examples include “I did not change jobs for fear of losing health 
insurance” and “I was encouraged to leave my job” because of the cancer. 
Post-traumatic stress 
The PTSD Checklist-Civilian Version (PCL-C) assesses symptomatology in 
non-combat populations by presenting a self-report symptom checklist that closely 
mirrors criteria set forth by the Diagnostic and Statistical Manual of Mental 
Disorders, IV (DSM-IV) for a formal diagnosis of PTSD.17,18 The instructions were 
modified so that symptoms were keyed to the particular traumatic stressor of 
interest; specifically, survivors were asked to rate each PTSD symptom in the past 4 
weeks with respect to their diagnosis and treatment for lymphoma. Each of 17 
symptoms is rated with respect to intensity on a scale of 1=not at all to 5=extremely 
bothersome, and item scores are summed to create a total that can range from 17-
85. Two approaches were used to identify PTSD: 1) the cut-off method, in which 
those with scores ≥ 44 are classified as having PTSD;19 and 2) the symptom cluster 
method, which follows the DSM-IV criteria for PTSD in that individuals who report 
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having been at least moderately bothered by (score ≥3) one or more re-experiencing 
symptoms (of 5; e.g., nightmares), three or more avoidance symptoms (of 7; e.g., 
evading follow-ups), and two or more arousal symptoms (of 5; e.g., easily startled), 
are classified as having PTSD.17 Using the PCL-C cut-off of 44, Blanchard et al.19 
reported a sensitivity of 0.94 and specificity of 0.86 with the Clinician Administered 
PTSD Scale (CAPS). In other work, the PCL-C demonstrated an α=.97, test-retest 
reliability of .96, and convergent validity of .93 with the Mississippi Scale in a sample 
of 123 Vietnam veterans.18 In this study, the total score yielded an α=.91, and the 
subscales produced the following internal consistency: re-experiencing α=.88, 
avoidance α=.82, and arousal α=.78.  
Statistical methods 
To assure that the PTSD prevalence estimates reflected the Tumor Registry 
sampling frame, sample prevalence estimates were adjusted for non-response 
based on race (African American, non-African American), as well as current age and 
age at diagnosis (in twenty-year increments). While the dataset overall had a small 
amount of missing data, the level of missingness in three variables, income (10.6%), 
stage (13.5%), and disease status (10.9%), justified multiple imputation via the 
Markov chain Monte Carlo (MCMC) algorithm.20 All variables in the conceptual 
model were included in the MCMC algorithm, but imputed values for the outcome 
variable (PCL-C) were not generated. Twenty datasets containing imputed values 
were used in the multiple linear and logistic regression analyses and standard errors 
adjusted for imputation were estimated in the SAS MIANALYZE procedure.21 
Bivariate analyses compared mean levels of PCL-C for those with and without a 
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given potential risk factor using t-tests and ANOVA. Pearson correlations were 
calculated between the PCL-C and all continuous independent variables. Multiple 
linear regression was used to estimate the independent associations between 
candidate variables and the continuous PCL-C score; logistic regression was used 
to estimate the associations of the same variables with meeting criteria for full or 
partial PTSD, as defined by the symptom cluster method. Variables were selected 
for inclusion in the multivariable models if they were at least marginally significant 
(P<.10) in bivariate analyses. Data management and bivariate analyses were carried 
out with SPSS Version 14.0. Multiple imputation and multivariable analyses were 
conducted using SAS Version 9.1.3.  
RESULTS 
 
Of the 1312 eligible survivors who were mailed a survey, 117 (9%) of the 
packages were returned undelivered and tracing attempts were unsuccessful. Of the 
remaining 1195 survivors who were assumed to have received a survey, 886 (74%) 
completed and returned their surveys, 258 (22%) did not respond, and 51 (4%) 
refused participation. Sample bias analyses using demographic information from the 
registries indicated that participating survivors were less frequently African American 
(10% vs. 20%, P<.001), older at study enrollment (mean age 62.9 vs. 58.8 years, 
P<.001), and older at diagnosis (52.6 vs. 48.1 years, P<.001) than non-participants.  
The 868 survivors who completed the PCL-C were included in further analyses. 
The sample characteristics are listed in Table 2.1. A similar number of females and 
males participated, 14% were non-Caucasian, 25% earned less than $30,000 
annually, 38% had a college degree, and 40% were employed. Mean age at study 
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enrollment was 63 and almost half (46%) were older adults (≥ 65 years of age). The 
majority of subjects reported having received chemotherapy treatment (78%) and 
that they were not currently in treatment for NHL (85%). The mean age at lymphoma 
diagnosis was 53 (range, 19-87). The mean interval from diagnosis to study 
enrollment was 10.2 years (range, 2-44 years). Having received a second primary 
cancer diagnosis was cited by 14% of the sample, and 4% were currently receiving 
treatment for it. Participants cited an average of 2.9 co-morbid conditions (SD, 2.1; 
range, 0-12), primarily back pain (42%), high blood pressure (40%) and heart 
disease (26%), and 1% had AIDS-related NHL. Scores on the psychosocial 
variables were: for social support, 83.1 (SD, 16.4; range, 20-100); appraisal of life 
threat, 19.3 (SD, 6.0; range, 6-30); and cancer-related employment and insurance 
issues, 1.1 (SD, 2.1; range, 0-17). 
The overall mean PCL-C score in this sample was 27.0 (SD=9.9), with 
subscale scores of 6.9 (3.1) for re-experiencing, 9.3 (3.8) for arousal, and 10.8 (4.4) 
for avoidance. As shown in Table 2.2, the prevalence of cancer-related PTSD in the 
sample was similar using the cut-off score (6.9%) and symptom cluster (7.6%) 
methods. After applying weights to account for non-response bias, the adjusted 
prevalence rose to 7.4% and 7.9% for each of these methods. Seventeen percent 
rated at least two of the three PTSD symptom clusters (partial or full PTSD) as 
occurring moderately to extremely often. Across the symptom clusters, 30% met the 
criteria for arousal, 20% for re-experiencing, and 14% for avoidance. Overall, 39% 
met criteria for at least one PTSD symptom cluster.  
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Relationship of PTSD Symptoms to Other Variables 
Bivariate associations between PCL-C scores and the independent variables 
are shown in Table 2.3. Among demographic and clinical variables, those who were 
non-Caucasian, had an annual income under $30,000, did not obtain a college 
degree, were younger, received a bone marrow or stem cell transplant, received 
biologic treatment, were currently receiving treatment for NHL, had active disease, 
and experienced at least one NHL recurrence had higher PCL-C scores (all P≤.01). 
Among the continuous variables, the strongest PCL-C relationships (all P<.001) 
were for co-morbidity (r=0.27), social support (r=-0.36), appraisal of life threat and 
treatment intensity (r=0.37), and cancer-related insurance and employment issues 
(r=0.27). In addition, significant PCL-C associations were found for age at study 
enrollment (r=-0.15), initial stage of disease (r=0.11), sum of treatment types 
(r=0.13), number of NHL-related visits to a physician (r=0.19), age at diagnosis (r=-
0.08), time since diagnosis (r=-0.11), and time since last physical exam (r=0.08). 
Regression Analyses 
Table 2.4 displays the results of a multiple linear regression for the PCL-C 
score and logistic regression for partial or full PTSD (i.e., at least two symptom 
clusters) for those variables at least marginally significant in the bivariate analyses 
(P<.10). Non-Caucasian race, less education, younger age at enrollment, having 
active NHL disease, less time since diagnosis, more co-morbidity, less social 
support, more negative appraisals, and more insurance and employment issues 
were independently associated with worse PCL-C scores. For example, survivors 
with active disease had PCL-C scores 3.7 points higher than those in remission or 
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cured (P=.001). Furthermore, survivors of non-Caucasian race had PCL-C scores 
2.4 points higher than those of Caucasian race (P=.004). The full model accounted 
for 38.5% of the variance (P<.001).  
In the logistic regression model, three risk factors (non-Caucasian race, 
younger age, active disease status) that were identified in the linear regression were 
not independently associated with PTSD symptoms, although race remained 
marginally statistically significant (P=.07), with Non-Caucasians having 1.7 times 
greater odds of having partial or full PTSD than Caucasians. Furthermore, when a 
logistic model for full PTSD (symptom clusters=3; 7.9% of sample) was estimated, 
the odds ratio for non-Caucasian race was 2.8 (95%CI=1.4, 5.8) and for active 
disease was 4.3 (95%CI=1.5, 12.2). Finally, education, time since diagnosis, co-
morbidity, and all psychosocial variables (social support, appraisals, and 
employment and insurance issues) had independent associations with PTSD 
symptoms. 
DISCUSSION 
 
This study is one of the first examinations of well-being among long-term 
survivors of NHL, who report varying degrees of PTSD symptomatology. Although 
the prevalence in this sample is somewhat lower than that found in some other 
traumatized populations, our adjusted prevalence of 7.4%-7.9% is more than three 
times the 2.4% prevalence in the general adult population.22,23 While prevalence 
estimates are highly dependent on the methodology and sample, our finding is 
similar to breast cancer survivors (for whom  PTSD prevalence of 5%-6% has been 
reported).3,4 Our prevalence was adjusted upwards by approximately 0.5% (6.9%-
  19 
7.4%) when accounting for non-response, suggesting that similar and previous 
studies of cancer survivors may be under-reporting PTSD if they had response 
patterns similar to those in our study.  
While the majority of survivors (61%) were not symptomatic for PTSD (i.e. had 
no symptom clusters), the prevalence in certain subgroups is cause for concern. For 
example, nearly 16% of non-Caucasians qualified for a full PTSD diagnosis. The 
greater PTSD symptomatology among non-Caucasians persists after adjustment for 
other demographic and clinical factors, indicating that the discrepancy is not due 
solely to differences in education or disease status. A possible explanation for this 
disparity is that individuals exposed to discrimination and prejudice may already be 
living with a heightened sense of arousal and greater stress.  
In two other sub-groups, 15% of those with active NHL disease and 12% of 
younger survivors (<50 years of age) met criteria for PTSD. Survivors with current 
disease may experience daily reminders of their illness, such as pain, itchiness, and 
fever. In support of this finding, Deimling et al.24 found that current cancer-related 
symptoms were the strongest predictor of hyper-arousal in a study of 180 adult, 
long-term cancer survivors. However, it is worth noting that results from a multiple 
regression that excluded individuals with active disease in our sample were 
substantively the same. Regarding age, Kornblith et al.7 suggest that younger 
survivors have less experience than their older counterparts in dealing with medical 
crises and life threats, thereby feeling more distressed overall. Furthermore, they 
may already be faced with more challenges at this earlier stage in the life cycle; for 
example, younger survivors had significantly more cancer-related employment and 
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insurance issues than did their older counterparts (mean: 1.7 vs. 0.9, P<.001), 
largely attributable to the higher employment rate (75.8% vs. 31.7%).  In addition to 
increasing age being a protective factor for PTSD, the passage of time seems to 
mitigate the impact of a cancer diagnosis and treatment. Perhaps least surprising 
was the finding that other health-related stressors (i.e., co-morbidities) were 
predictive of PTSD symptomatology.  
It is encouraging to consider that the psychosocial factors related to PTSD are 
potentially modifiable. For example, cognitive behavioral (CBT) and prolonged 
exposure techniques have been shown to be effective in reducing or eliminating 
PTSD symptoms in other traumatized populations, such as survivors of sexual 
assault,25 but the efficacy of psychosocial treatments on cancer-related PTSD is just 
beginning to be examined.26 Interventions that combine therapeutic approaches 
(e.g., CBT, support groups) may be desirable, as we found social support to be 
correlated most strongly with avoidance symptoms (r=-0.41, P<.001) and negative 
appraisals most related to re-experiencing symptoms (r=0.36, P<.001).  
This study has some limitations, including the absence of a comparison group, a 
cross-sectional study design, and inclusion only of patients treated at two large 
comprehensive cancer centers. Without a comparison group it is difficult to 
determine if these NHL survivors had more or less PTSD symptomatology than a 
similar group of people who never had NHL. However, the markedly higher PTSD 
prevalence in our sample compared to general population estimates suggests that 
NHL survivors have elevated PTSD symptomatology, supporting the need to 
address it.  
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The cross-sectional design prevents determination of whether PTSD 
symptomatology or certain risk factors (e.g., low social support) occurred first. 
However, it is reasonable to assume that many of the risk factors (e.g., non-
Caucasian race, less education) preceded the PTSD. Further, this limitation should 
not affect the prevalence estimates except to the extent that the sample is a mix of 
individuals at different places in their course of survivorship. Finally, the inclusion of 
patients from only two large comprehensive cancer centers may limit the 
generalizability of our results to survivors living in other regions and treated at 
smaller hospitals. However, our demographic profile closely mirrors that of the 
national population of NHL survivors, thereby strengthening the robustness and 
generalizability of our prevalence estimates. Study strengths include a high 
response rate (74%), adjustment for non-response, sophisticated and appropriate 
methodology for accounting for missing data, two methods (linear and logistic 
regression) for identifying PTSD risk factors, and a balanced gender ratio.  
In closing, while the majority of survivors did not exhibit symptoms of PTSD, the 
impact of diagnosis and treatment for cancer persists for many, such as having 
physical reactions to reminders (trouble breathing, sweating), difficulties in 
concentration and sleep, detachment from others, and avoiding medical care. 
Identification of those at risk (e.g., non-Caucasian, less education) early in the 
survivorship trajectory could promote screening and treatment to minimize PTSD 
symptomatology.  
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Table 2.1. Characteristics of the Study Sample (N=886) 
 
Demographics     N       %  Clinical Characteristics for NHL      N        % 
Gender 
  
 
Histology                                        
Male 435  49.1 
 
Indolent 445  50.2 
Female 451  50.9 
 
Aggressive 391 44.2 
Race                  
  
 
Unknown 50 5.6 
Caucasian    758  85.5 
 
Stage at diagnosis    
African-American   91  10.3 
 
Stage I 247 27.9 
Multiple race 30  3.4 
 
Stage II 159 17.9 
Other  7  .8 
 
Stage III 146 16.5 
Ethnicity 
  
 
Stage IV 214 24.2 
Non-Hispanic 873  98.5 
 
Unknown 120 13.5 
Hispanic 13  1.5 
 
Types of treatment: mean (SD)    2.1 (1.1) 
Income level 
  
 
No treatment 45  5.1 
< $30,000 225  25.4  Surgery 248  28.0 
$30,000 - $59,999 239  27.0  Radiation therapy 418  47.1 
$60,000 - $89,999 139  15.7  Chemotherapy 692  78.1 
≥ $90,000 189  21.3  Bone marrow/stem cell transplant 132  14.9 
Unknown 94  10.6 
 
Biologic therapy 261  29.5 
Education  
  
 
Other therapy  104  11.7 
High school or less 
 250  28.2  
 
Current treatment status    
Some college or trade 
school 277  31.3  
 
Not in treatment 752  84.9 
College degree 199  22.5 
 
Receiving treatment    117  13.2 
Post-graduate 138 15.6 
 
Unknown 17 1.9 
Unknown 22 2.4 
 
Disease status     
Marital status 
  
 
In remission or cured  680 76.7 
Married 648  73.1 
 
Not in remission  109  12.3 
Living with partner 24  2.7 
 
Unknown 97 11.0 
Widowed  90  10.2 
 
Number of recurrences  
Separated/divorced 48  5.4 
 
0 562 63.4
Single 67  7.6 
 
≥1 293 33.1 
Unknown 9  1.0 
 
Unknown 31 3.5
Employment status 
  
 
Frequency of visits 
Retired 477  53.8 
 
0 172 19.4
Employed 350 39.5 
 
1-2 126 14.2
Unemployed 46 5.2 
 
3-4 138 15.6
Unknown 13  1.5 
 
5-6 131 14.8 
Age at enrollment 
  
 
7-10 90 10.2
Mean (SD) 62.9 (13.5)  11-20 86 9.7
Range 25–92 
 
>20 113 12.8
25-49 157 17.7 
 
Unknown 30 3.4 
50-64 323 36.5 
 
Site of treatment   
65-79 315  35.6 
 
Duke University  750 84.7 
80+ 91 10.2 
 
University of North Carolina 136 15.3
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Age at diagnosis: mean (SD) 52.6 (14.2) 
 Health Status   
 
Range: 19-87 
Secondary cancer (s)    19-49 370 41.8 
Yes 120 13.5 
 
50-64 337 38.0 
No 752 84.9 
 
65-79 168 19.0 
Unknown 14 1.6 
 
≥80 11 1.2 
Co-morbidities: mean (SD)       2.9 (2.1)  Years since diagnosis: mean (SD) 10.2 (7.1) 
 0 97 10.9 
 
Range: 2-44 
 1-2 326 36.8 
 
2-4 yrs 219 24.7 
3-5 341 38.5 
 
5-9 yrs 335 37.8 
6-8 95 10.7 
 
10-14 yrs 150 16.9 
≥9 12 1.4 
 
15-19 yrs 88 9.9 
Unknown 15 1.7 
 
≥20 yrs 94 10.6 
Years since last physical exam 
 
 
 
 
<1 year ago 480 54.2  Psychosocial  
1-2 years ago 186 21.0 
 
Social support: mean (SD) 83.1 (16.4) 
3-4 years ago 71 8.0  Range: 20-100 
≥ 5 years ago 128 14.4 
 
Unknown 21 2.4 
 
Appraisal of life threat and treatment 
intensity: mean (SD) 19.3 (6.0) 
 
  
 
Range: 6-30 
 
  
 
Employment and insurance issues 
related to cancer: mean (SD) 1.1 (2.1) 
 
  
 
Range: 0-17 
 
 
Abbreviations: SD, standard deviation; NHL, non-Hodgkin’s lymphoma 
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Table 2.2. Prevalence of Cancer-related Post-Traumatic Stress Disorder (PTSD) 
(N=868) 
 
 Non-Adjusted  Adjusted for  Non-response b 
Indicator of PTSD a % 95% CI  % 95% CI 
      Score ≥ 44 6.9 5.2-8.6  7.4 5.6-9.1 
3 Symptom clusters 7.6 5.8-9.4  7.9 6.1-9.7 
2 Symptom clusters     8.9 7.0-10.8  9.1 7.2-11.0 
      1 Symptom cluster 22.2 19.5-25.0  22.3 19.5-25.0 
No Symptom clusters 61.3 58.1-64.5  60.7 57.5-64.0 
a
  Based on the PTSD Checklist-Civilian Version (PCL-C).  Symptom 
clusters include  ≥ 3 avoidance symptoms, ≥ 2 arousal symptoms, and ≥ 1 
re-experiencing symptom.  All three clusters constitute full PTSD.  
b
  Adjusted for current age, age at diagnosis, and race. 
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Table 2.3. Bivariate Associations of Patient Characteristics with PTSD Symptoms 
(PCL-C Score) a 
 
n 
Mean or 
correlation 
 
(SD) 
 
p-value b 
Demographics 
    
Gender     
   Male 429 26.8 (9.9) .511 
   Female 439 27.2 (9.9)  
Race     
   Caucasian 745 26.4 (9.1) ref<.001 
   African American 85 29.1 (12.8) .064 
   American Indian 3 34.7 (6.5) .118 
   Asian 2 32.5 (13.4) .347 
   Mixed Race 30 33.8 (13.1) .005 
   Other 3 43.3 (21.9) .313 
Ethnicity     
   Hispanic 13 31.9 (15.7) .276 
   Non-Hispanic 855 27.0 (9.8)  
Income  r = -.148  <.001 
   < $30,000 217 29.6 (11.4) ref<.001 
   $30,000 - $59,999 238 26.6 (9.8) .003 
   $60,000 - $89,999 138 26.5 (9.50 .006 
   ≥ $90,000 189 25.3 (8.0) <.001 
Education  r = -.110  .001 
   High school or less 243 28.9 (11.1) <.001 
   Some college or trade school 276 27.2 (10.4) .017 
   College+ 333 25.4 (7.9)   ref<.001 
Marital status     
   Married 642 26.8 (9.8)   ref.095 
   Living with partner 24 29.0 (9.3) .277 
   Widowed 88 26.7 (9.3) .915 
   Separated 5 37.4 (11.2) .017 
   Divorced 43 26.5 (7.8) .851 
   Single 63 28.9 (12.2) .184 
Employment status     
Employed 346 26.4 (8.9) ref.117 
Unemployed 43 29.6 (12.2) .106 
Retired 466 27.1 (10.1) .300 
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Age at enrollment (yrs)  r = -.145  <.001 
   25-49 152 29.1 (11.5) ref<.001 
   50-64 317 27.8 (10.2) .221 
   65-79 311 25.9 (8.8) .003 
   80+ 88 24.6 (8.4) .001 
Clinical characteristics for NHL 
 
   
Histology     
Aggressive 384 26.7 (9.6) .491 
Indolent 437 27.2 (10.2)  
Stage at diagnosis  r = .106  .004 
1 244 25.4 (8.6) ref.015 
2 153 27.4 (9.1) .027 
3 145 28.0 (10.3) .008 
4 212 28.0 (10.9) .006 
Sum of treatment types ever  r = .128  <.001 
0 35 27.0 (12.2) ref<.001 
1 216 26.2 (9.1) .655 
2 338 26.1 (8.8) .581 
3 192 27.4 (10.1) .840 
4 65 31.1 (12.4) .118 
5 19 34.1 (15.5) .072 
6 2 28.0 (4.2) .912 
Surgery     
Yes 245 27.8 (10.5) .188 
No 599 26.8 (9.7)  
Radiation therapy     
Yes 415 27.1 (10.3) .937 
No 453 27.0 (9.6)  
Chemotherapy     
Yes 685 27.3 (9.9) .100 
No 183 26.0 (10.0)  
Bone marrow or stem cell 
transplant     
Yes 131 30.9 (12.8) <.001 
No 737 26.3 (9.1)  
Biologic treatment     
Yes 260 28.4 (10.9) .010 
No 608 26.5 (9.4)  
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a
 PTSD Checklist – Civilian Version 
b
 P-values shown as superscripts are for the overall F-test for the categorical 
variable with k-1 degrees of freedom where k is the number of categories.  
Abbreviations: SD, standard deviation; UNC, University of North Carolina 
Current treatment      
Yes 116 29.1 (10.2) .012 
No 743 26.6 (9.7)  
Active disease     
Yes 107 30.5 (12.1) .001 
No 675 26.1 (9.0)  
Recurrence(s)     
Yes 291 28.5 (10.8) .002 
No 554 26.2 (9.4)  
Frequency of visits  r =  .193  <.001 
0 167 24.6 (8.2) ref<.001 
1-2 125 26.0 (9.1) .185 
3-4 137 26.5 (9.6) .063 
5-6 129 26.4 (8.4) .066 
7-10 89 28.6 (10.9) .001 
11-20 85 28.9 (10.6) <.001 
>20 112 30.8 (12.4) <.001 
Site of treatment     
Duke 735 26.8 (9.6) .063 
UNC 133 28.5 (11.1)  
Age at diagnosis (years)  r = -.083  .015 
Time since diagnosis (years)  r = -.108  .001 
Health status 
    
Co-morbidity  (0-30)  r = .273  <.001 
Time since last physical exam 
(years)  r = .085  .013 
Secondary cancer     
Yes 119 27.0 (9.3) .989 
No 743 27.0 (10.0)  
Psychosocial 
    
Social support (20-100)  r = -.355  <.001 
Appraisal of life threat and 
treatment intensity (6-30)  r = .369  <.001 
Insurance and employment issues 
related to cancer (0-24)  r = .274  <.001 
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Table 2.4. Multiple Linear Regression for PCL-C a Score and Logistic Regression for 
Meeting Symptom Criteria for Full or Partial PTSD (N=868) 
 
 
PCL-C   Partial or Full PTSD f 
  Variable Estimate (95% CI) P-value  Odds Ratio  (95% CI) P-value 
  Demographics        
Non-Caucasian race b 2.37 (0.75, 3.99) .004  1.67  (0.96, 2.91) .070 
Income c 0.29 (-0.31, 0.90) .346  1.16 (0.91, 1.47) .222 
Education d 
-1.46 (-2.26, -0.66) <.001  0.72 (0.53, 0.97) .032 
Age at enrollment (per 10 years) 
-0.60 (-1.05, -0.14) .010  0.89 (0.75, 1.05) .169 
  Clinical characteristics for NHL 
   
 
   
Initial stage of disease (1-4) 
-0.01 (-0.52, 0.51) .978  0.96 (0.79, 1.16) .652 
Bone or stem cell transplant b 1.43 (-0.27, 3.14) .100  0.98 (0.54, 1.79) .949 
Biologic treatment b 
-0.42 (-1.77, 0.93) .539  1.10 (0.66, 1.83) .718 
Current treatment b 
-1.24 (-3.44, 0.96) .270  0.59 (0.26, 1.33) .203 
Active NHL disease b 3.69 (1.49, 5.89) .001  1.79 (0.86, 3.74) .121 
Any recurrence b 0.75 (-0.53, 2.02) .253  1.19 (0.73, 1.93) .487 
Number of visits  0.29 (-0.04, 0.61) .089  0.98 (0.86, 1.10) .693 
Time since diagnosis (years) -0.15 (-0.23, -0.06) <.001  0.93 (0.89, 0.97) <.001 
  Health status 
   
 
   
Co-morbidity e    0.44 (0.32, 0.56) <.001  1.10 (1.06, 1.15) <.001 
Time since last physical (years) -0.06 (-0.56, 0.44) .823  0.94 (0.78, 1.14) .514 
  Psychosocial 
   
 
   
Social support 
-0.17 (-0.21, -0.14) <.001  0.97 (0.96, 0.98) <.001 
Appraisal of life threat & 
treatment intensity  0.49 (0.39, 0.59) <.001 
 1.12 (1.07, 1.17) <.001 
Insurance/employment issues  0.45 (0.17, 0.73) .002  1.15 (1.05, 1.25) .002 
 
       
 
 
NOTE: All analyses conducted with imputed data and adjusted for site of treatment (Duke, 
UNC). Variables included in this table are those that were significantly associated with the PCL-
C score (P<.10) in the bivariate analyses. 
a
 PTSD Checklist – Civilian Version 
b
 Coded as a dichotomy, yes (1) or no (0) 
c
 Coded as 1≤$30,000, 2= $30,000-$59,999, 3= $60,000-$89,999, 4= ≥$90,000 
d
 Coded as 1= high school or less, 2= some college, 3= college graduate 
e
 Self-Administered Co-morbidity Questionnaire 
f Number of events/cases= 148/868 
Abbreviations: CI, confidence interval 
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Figure 2.1. Conceptual model of cancer-related Post-Traumatic Stress Disorder 
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INTRODUCTION 
The devastating message, “you have cancer”, has been delivered to over ten 
million Americans living today, representing roughly 3.6 percent of the US 
population.1 Two-thirds of these individuals were diagnosed more than five years 
ago, and it is not uncommon for long-term survivors to recall the actual event with 
strong emotions and in great detail. The cancer experience (diagnosis, treatments, 
and post-treatment recovery/monitoring) is now categorized as a “traumatic event” 
according to the Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV),2 in 
recognition that survivors are at increased risk for post-traumatic stress disorder 
(PTSD). PTSD is a set of symptoms (re-experiencing, avoidance, and arousal) 
following direct exposure to an extreme traumatic stressor where the individual is 
involved in, witnesses, or learns about threatened death or serious injury.2 Cancer-
related PTSD has been estimated in 5 to 8 percent of the adult survivors studied 
(Smith, Zimmerman, Williams, Preisser, & Clipp, in review).3, 4 
While research has largely focused on negative sequelae such as PTSD, a 
second focus has emerged on the initiation of positive changes and resiliency 
resulting from the cancer experience; this is generally referred to as post-traumatic 
growth (PTG). However, the effects of cancer-related outcomes including PTSD and 
PTG on physical, emotional, social and functional well-being and quality of life (QOL) 
remain largely unknown, despite the implied urgency brought about by the aging of 
the US population and subsequent doubling of the annual incidence from 1.3 million 
new cancer patients in 2000 to over 2.6 million by 2050.5 Furthermore, little is known 
about the QOL of individuals diagnosed with non-Hodgkin’s lymphoma (NHL), the 
sixth most common cancer in the US which has experienced a doubling in incidence 
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rates since the early 1970’s.6 Therefore, the primary purpose of this paper is to 
evaluate whether PTSD and PTG help to explain the role of risk factors in relating to 
QOL in NHL survivors, thereby enhancing our understanding of the cancer 
experience so that processes could be targeted for intervention.  
Cancer-related Trauma and QOL 
 
A conceptual model of QOL among cancer survivors is proposed in Figure 
3.1, in which stress, coping, and adaptation theories7, 8 emphasize the relationship 
between the person (characteristics of the person including demographics and 
psychosocial components) and his or her environment (nature of the environmental 
event, in this case the stressors). Psychological effects are a byproduct of this 
relationship, one of which occurs when the stress of cancer diagnosis and treatment 
is appraised as taxing or exceeding one’s resources and endangering one’s well-
being (i.e., PTSD).   
Alternatively, the effect can be growth inducing as in the case of PTG, which 
is characterized by positive changes in an individual as a result of a traumatic event. 
PTG is best explained by the information processing theory, in which life events are 
organized into schemas that manage the processing of the traumatic event. When a 
trauma occurs, an individual’s “world schema” is disrupted in which the world may no 
longer be seen as physically and psychologically safe. In addition, a person’s self-
schema of being competent and self-reliant may be challenged. When individuals 
are able to integrate the threat with existing schemas, it is said to represent the 
“completion tendency”.9  This is accomplished through altering the meaning of the 
experience to fit into existing schemas (assimilation) or changing the schemas 
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(accommodation) to conform to the new information. According to Tedeschi and 
Calhoun,10 PTG is more likely to develop when cognitive rebuilding takes into 
account the changed reality of one’s life after the trauma and produces schemas that 
incorporate the trauma and future events, which are then more resistant to being 
shattered.   
Building upon the theoretical base, characteristics identified in previous 
research studies that were related to QOL, PTSD, and PTG in cancer survivors were 
incorporated into the conceptual model (Smith, Zimmerman, Williams, Preisser, & 
Clipp, in review).3, 11, 12  Clinical characteristics (e.g., cancer treatments, post-
treatment monitoring) and health status (e.g., co-morbidity) are conceptualized as 
stressors, while social support, appraisals and insurance and employment-related 
issues represent psychosocial characteristics that can influence the outcome of 
these stressors. For example, the nature and quality of social support can affect the 
individual’s likelihood of timely follow-up, in addition to influencing appraisals of life 
threat; these can either diminish or enhance the coping strategies employed by the 
individual, thereby leading to negative (PTSD) and/or positive (PTG) psychological 
effects.  
More specifically, we hypothesize that PTSD and PTG directly relate to QOL 
and also mediate the effects of demographic, psychosocial, and clinical/health status 
risk factors (e.g., race, co-morbidity, social support) on QOL. This hypothesis was 
tested using Structural Equation Modeling (SEM).13 While the primary aim of this 
study is to determine whether some or all of the factors have indirect and direct 
relationships with QOL (i.e., partial mediation), competing models are presented 
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which examine if QOL can be better explained by the factors having only an indirect 
relationship (full mediation) or direct relationship (no mediation).  
METHODS 
Participants and Procedures 
Potential study participants were identified through Tumor Registries at the 
Duke and University of North Carolina (UNC) Lineberger Comprehensive Cancer 
Centers and were contacted by mail following physician approval. Approval for all 
procedures was granted by the Institutional Review Boards at the UNC and Duke 
Schools of Medicine. Individuals were eligible for this study if they were diagnosed 
with adult NHL (≥19 years old at diagnosis, and ≥2 years post-diagnosis). 
Prospective participants were sent a letter signed by their physician, a self-
administered questionnaire, a $2 bill incentive, and thank-you/reminder postcards. 
Non-respondents were sent replacement mailings and followed up by telephone to 
confirm receipt of the survey packet.  
Measures 
Demographic and Clinical Characteristics 
Demographic information such as birth date, gender, race, ethnicity, marital 
status, income, and education was collected via self-report. The Tumor Registry 
databases were used to obtain details regarding diagnosis (e.g., date, histology) and 
treatment history. NHL histology was categorized as indolent or aggressive based 
on the updated Revised European American Lymphoma/World Health Organization 
(REAL/WHO) classification system.14 
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Health Status 
The Self-administered Co-morbidity Questionnaire (SCQ)15 was used to 
assess other non-NHL health-related problems, with up to 3 points for each of 12 
conditions, depending on severity. In addition, selected questions related to 
healthcare use and secondary cancer status were adapted for use from the 
Childhood Cancer Survivor Study survey.16 
Psychosocial 
The 20-item Medical Outcomes Study-Social Support Survey (MOS-SSS) 
was used to measure the perceived availability of social support,17 with scores 
ranging from 20-100 (α=.97 in this study).  The Appraisal of Life Threat and 
Treatment Intensity Questionnaire (ALTTIQ; six items, range 6-30; α=.80) was used 
to assess the extent to which cancer and its treatment are perceived to be life-
threatening and intense.18 Finally, to assess employment and insurance-related 
situations and difficulties, 24 questions (possible range 0-24, α=.82) were derived 
from an instrument developed by the Cancer and Leukemia Group B (CALGB) 
clinical research group.19 
Psychological Effects 
The PTSD Checklist-Civilian Version (PCL-C) assesses symptomatology in 
non-combat populations by presenting a self-report symptom checklist that closely 
mirrors criteria set forth by the DSM-IV for a formal diagnosis of PTSD.2, 20 The 
instructions were modified for the current study to focus on the particular traumatic 
stressor of interest; specifically, survivors were asked to rate each PTSD symptom in 
the past 4 weeks with respect to their diagnosis and treatment for lymphoma. The 
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symptom cluster scoring method was used in the analysis, which maps to the DSM-
IV criteria for PTSD.2 In this study, the total score yielded an α=.91, and the internal 
consistency of the subscales were α=.88 (re-experiencing), α=.82 (avoidance), and 
α=.78 (arousal).  
 The Post-traumatic Growth Inventory (PTGI) is a 21-item scale that was used 
to measure positive life changes following a cancer-related trauma.10 The overall 
α=.96, with the five domains showing strong internal consistency: relating to others 
(α=.92); new possibilities (α=.88); personal strength (α=.86); spiritual change 
(α=.89); and appreciation of life (α=.80).  
Quality of Life 
The Functional Assessment of Cancer Therapy – General Version (FACT-G) 
is a 27-item self-report measure designed to assess QOL specifically for cancer 
patients, and has good reported internal consistency.21 The internal consistency 
reliability in our sample was excellent: physical well-being (α=.87); emotional well-
being (α=.77); functional well-being (α=.88); social/family well-being (α=.80); and 
FACT-G total score (α=.93). 
Statistical Methods 
Pearson product moment correlations and associated statistical significance 
were calculated between QOL, as measured by the FACT-G, and all continuous 
demographic, clinical, health status and psychosocial variables. T-tests or ANOVA 
compared mean FACT-G scores for those at different levels of potential categorical 
risk factors. A multiple linear regression model for the FACT-G score was estimated 
in order to identify candidates for inclusion in the SEM model. Variables were 
  39 
selected for inclusion in the multiple linear regression model if they were significant 
(P<.05) in the bivariate analyses. Missing data in three potential risk factors, income 
(10.6%), stage (13.5%), and disease status (10.9%) justified imputation, although 
the overall data set had a low level of missingness. Multiple imputation, via the 
Markov chain Monte Carlo (MCMC) algorithm, was used to impute values for 
missing data in the independent variables (excluding the mediators).22 Twenty 
datasets containing imputed values were used in the multiple linear regression and 
standard errors adjusted for imputation were estimated in the SAS MIANALYZE 
procedure.23 
Variables that were independently associated with the FACT-G score (P<.05 
in the multiple linear regression model) were selected for inclusion in the SEM 
model. The hypothesized mediation model of PTSD, PTG and QOL was tested and 
compared with two alternate models of no mediation and full mediation using 
MPLUS V4.224 with the weighted least square means and variance adjusted method 
of estimation, an approach used when both categorical and continuous variables are 
included in a model.   
To assess the overall fit of the models, the following indices were examined: 
the Tucker-Lewis Index (TLI),25 the comparative fit index (CFI),26 and the root mean 
square error of approximation (RMSEA).27 Good fit is indicated by values of .90 or 
greater for the TLI and CFI28 and .05 or smaller for the RMSEA, while values 
between .05 and .08 represent adequate fit.29 Data management and bivariate 
analyses were carried out with SPSS V14.0. Multiple imputation and multiple linear 
regression analyses were conducted using SAS V9.1.3.  
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RESULTS 
 
Of the 1195 eligible survivors who were assumed to have received a mailed 
survey, 886 (74%) returned their surveys. Participating survivors were less 
frequently African American (10% vs. 20%, P<.001), older at study enrollment (mean 
age 62.9 vs. 58.8 years, P<.001), and older at diagnosis (52.6 vs. 48.1 years, 
P<.001) than non-participants.  The 830 survivors who completed the FACT-G, PCL-
C, and PTGI were included in the analyses; their characteristics are listed in Table 
3.1. A similar number of females and males participated; 13.5% were non-
Caucasian; 27.3% earned less than $30,000 annually; 40.1% had a college degree; 
25.4% were unmarried or not living with a partner; and 40.7% were employed. Mean 
age at study enrollment was 62.8 and almost half (45.5%) were older adults (≥ 65 
years of age). The mean number of treatment types reported was 2.1; most (86.6%) 
were not receiving treatment; and the majority (78.0%) were in remission or cured. 
The mean interval from diagnosis to study enrollment was 10.4 years (SD, 7.3; 
range, 2-44 years). Participants reported an average of 2.9 co-morbid conditions 
(SD, 2.2; range, 0-12). The mean score for social support was high (83.3; SD, 16.3; 
range, 20-100), while that for appraisals was more mid-range (19.4; SD, 5.9; range, 
6-30), and for cancer-related employment and insurance issues was low (1.1; SD, 
2.1; range, 0-17). The mean number of PTSD symptom clusters in this sample was 
0.6 (SD=0.9), with 19.2% of the sample meeting the criteria for re-experiencing, 
30.0% for arousal, and 13.7% for avoidance. The mean PTGI score was 60.4 (SD, 
24.6), with domain mean scores above the mid-range with the exception of new 
possibilities, which was below (11.0; SD, 6.4; range, 0-25).   
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Relationship of QOL to Other Variables 
Bivariate associations between QOL (FACT-G scores) and the independent 
variables are also given in Table 3.1. Among demographic and clinical variables, 
those who were non-Caucasian, had an annual income under $30,000, did not 
obtain a college degree, were not married, were not employed, were younger, were 
of a later stage at diagnosis, had more types of treatment, were currently receiving 
treatment for NHL, had active disease, or had experienced at least one NHL 
recurrence had lower QOL (FACT-G scores; all P≤.01). Among the remaining 
variables, the strongest QOL relationships (all at P<.001) were for PTSD symptoms 
(r=-0.62), social support (r=0.49), and co-morbidity (r=-0.39).  
 As noted earlier, a multiple linear regression was conducted for the FACT-G 
total score and for those independent variables significant in the bivariate analyses 
(P<.05). Not having a college degree, not being employed, being a younger age at 
enrollment, having active NHL disease, more NHL-related visits, less time since 
diagnosis, more co-morbidity, less social support, more negative appraisals of life 
threat and treatment intensity, and more insurance and employment issues were 
significantly related to lower FACT-G scores in the regression. The full model 
accounted for 50% of the variance (R2=.501).  
Structural Equation Modeling 
 
A correlation matrix (Table 3.2) shows the relationships between 
demographic, clinical, health status, psychosocial, psychological effect, and QOL 
variables.  The measurement model included three latent variables (variables which 
are not measured directly): two exogenous variables (a variable that is not caused 
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by another variable in the model; PTSD symptom clusters, PTG) and one fully 
endogenous variable (a variable that is caused by one or more variables in the 
model; QOL). PTSD symptom clusters had three categorical/binary indicators (re-
experiencing, avoidance, arousal), PTG had five continuous indicators (relating to 
others, new possibilities, personal strength, spiritual change, appreciation of life), 
and QOL had four continuous indicators (physical, emotional, functional, 
social/family well-being).  
 The initial measurement model showed statistically significant loadings of 
each observed indicator on its corresponding latent construct (all at P<.001). 
However, further examination of the loadings suggested that the social/family well-
being indicator be dropped from QOL because its R-square (.285) was less than half 
of those of the remaining FACT-G domains (physical, .600; emotional, .599; 
functional, .761). Nevertheless, the social/family domain was retained due to 
theoretical considerations, and all four domains were included in the QOL construct 
for further analyses. 
Initially, a simple, unmediated hybrid model (Model B) was tested which 
included only direct effects of the independent and mediation (PTSD, PTG) variables 
with QOL. As shown in Table 3.3, the model fit was poor, RMSEA=.104, CFI=.722, 
TLI=.723. However, all coefficient paths were statistically significant at P<.01, 
confirming the independent relationship of each variable to QOL. Next, the 
hypothesized partial mediation model (Model A) was tested, which included paths 
from the independent variables to PTSD and PTG and from PTSD and PTG to QOL. 
In addition, to allow for the possibility that the independent variables have 
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relationships to QOL that are not mediated by PTSD and PTG, direct paths from the 
independent variables to QOL were included. The model fit was improved from the 
simple, unmediated Model B; RMSEA=.083, CFI=.827, TLI=.824. The next step was 
to test the full mediation model (Model C), which included paths from the 
independent variables to PTSD and PTG and from PTSD and PTG to QOL. The 
model fit improved from the unmediated Model B, but slightly degraded from that of 
the partial mediation Model A; RMSEA=.084, CFI=.798, TLI=.818. The hypothesized 
Model A was trimmed to include only statistically significant paths (P<.05), which 
resulted in the best fitting model (Model A’), RMSEA=.072, CFI=.868, TLI=.865. In 
addition, Model A’ explained a sizable amount of the variance (81.8%) in QOL in 
NHL survivors. The final model is displayed in Figure 3.2. 
In examining Figure 3.2 and using recommendations by Cohen30 and Kline13 
about the interpretations of the absolute magnitudes of path coefficients, “small” 
effect is indicated by standardized values <.10, “typical” or “medium” effect by values 
around .30, and “large” effects by values ≥ .50, we can conclude that of the 
mediators, PTG had a small (positive) effect while PTSD symptoms had a large 
(negative) effect on QOL.  More specifically, PTG mediated the relationship between 
(i.e., intervened between) appraisals, social support, college education, age, and 
active disease on QOL while PTSD symptoms mediated some of the same variables 
(appraisals, social support, and education) in addition to co-morbidity, years since 
diagnosis and employment and insurance issues. Only two of the independent 
variables (not being employed and NHL-related visits to a physician) were not 
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mediated by either PTSD symptoms or PTG; each had only a small direct (negative) 
relationship to QOL. 
The direct and indirect relationships of demographic (age, education, 
employment) and clinical (active disease, NHL-related visits, years since diagnosis) 
variables to QOL were small to medium, while health status (co-morbidity) and 
psychosocial (appraisals, social support) variables had greater (medium) direct and 
indirect relationships. For example, individuals with more social support reported 
more PTG, fewer PTSD symptoms and greater QOL, while those with more negative 
appraisals of life threat and treatment intensity reported more PTG and PTSD 
symptoms and lower QOL (all at P<.05), as shown in Figure 3.2. Finally, the 
unstandardized path coefficients for Model A’ are given in Table 3.4, which can be 
interpreted as regression coefficients.13 
 As demonstrated by these results, PTG and PTSD symptoms were significant 
mediators between demographic, clinical, health status, and psychosocial 
characteristics and QOL. This is substantiated by the smaller direct parameter 
estimates of these variables in the partially mediated model (Model A) than in the 
unmediated model (Model B). In addition, the paths to and from the mediated 
variables in Model A’ were all statistically significant (P<.05). Furthermore, the 
indirect (mediated) relationships were all statistically significant (P<.05), according to 
the conservative Sobel test.31 
DISCUSSION 
 
This is the first study to examine the mediating effects of trauma outcomes in 
explaining QOL in cancer survivors. Our results show that PTSD symptoms and 
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PTG help to explain the relationship between specific demographic, clinical, health 
status, and psychosocial variables and QOL. These findings give support to using 
PTSD as a diagnostic framework (and PTG, to a lesser extent) in understanding 
symptomatology in this population. However, given the absence of “good fit”, it is 
recommended that these findings be replicated with other measures and in other 
cancer samples to improve their robustness.  With replication, our findings suggest 
that attention be given to reducing PTSD symptomatology and enhancing PTG in 
cancer survivors as a way to improve their QOL.  
 Although there is an absence of comparable studies in cancer survivors, 
studies of war veterans have similarly found PTSD to mediate the relationship 
between antecedent variables and QOL.32-34 Additionally, several studies conducted 
with cancer survivors found negative relationships between PTSD and QOL,35-38 yet 
no such studies were identified in a Medline search of PTG and QOL. The dearth of 
literature regarding the association between PTG and QOL may be reflective of the 
more recent development of psychosocial models, as opposed to more traditional 
medical models that incorporate PTSD as a diagnostic disorder.  
 The QOL model that we tested (Figure 3.2) explained a large amount of the 
variance in well-being (82%), indicating that it includes many key variables and is 
relevant to NHL survivorship. Similar to Northouse et al.,39 we found that many of the 
clinical variables (e.g., stage of disease at diagnosis, sum of treatment types, NHL 
histology) contributed little or no unique variance in the survivors’ QOL, while 
psychosocial variables (social support, appraisals), health status (co-morbidity) and 
PTSD symptoms were important components of the model. Future screening, 
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assessment, treatment and research activities need to consider the significant 
relationship of these variables to survivors’ QOL. 
 The testing of alternative SEM models describing the pathways between the 
antecedent, mediator and outcome variables led to a reduction in the number of 
paths, thereby enhancing parsimony. It also elucidated the relationship between 
variables; for example, we found that some variables had a direct path to QOL (not 
employed, NHL-related visits to a physician), others had an indirect path (years 
since diagnosis, employment and insurance-related issues), and still others had both 
direct and indirect paths to QOL (active disease, age, college education, appraisals, 
social support, co-morbidity). Examining these pathways is an important exercise in 
unraveling the complex processes behind QOL so that interventions can be applied, 
and if necessary, developed for cancer survivors. For example, individuals with 
active disease or of an older age could be targeted for interventions aimed at 
enhancing PTG, while those without a college degree, more co-morbidity, more 
recent diagnosis or more employment and insurance issues related to cancer might 
benefit from treatments to reduce PTSD symptomatology as a means to improving 
overall QOL. In addition, individuals with lower social support could benefit from 
interventions focused on enhancing PTG and social support, and reducing PTSD 
symptoms. 
It is through understanding and testing for mediation that we can begin to 
untangle the mechanisms and processes by which the cancer experience affects an 
individual’s QOL. As stated by Baron and Kenny,40 mediator variables are those that 
“speak to how or why such effects occur”, representing processes that could be 
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targeted for intervention. To translate our findings to practice, treatments could be 
delivered that aim to reduce PTSD symptoms and enhance PTG.  For example, 
cognitive behavioral (CBT) and prolonged exposure techniques have been shown to 
be effective in reducing or eliminating PTSD symptoms in survivors of sexual 
assault.41 These proven therapies could be modified for use with cancer survivors to 
include methods that enhance PTG and address the unique features of a cancer-
related trauma. For example, targeted treatments could be developed and 
implemented that minimize future-oriented intrusions (fear of recurrence, test 
anxiety) and enhance coping skills as survivors navigate through a range of possible 
aversive events such as treatments, recurrence(s), and medical surveillance.  
Several limitations warrant caution in interpreting our findings. First, although 
our sample was representative of NHL patients treated at two major comprehensive 
cancer centers in North Carolina, the findings cannot be generalized beyond this 
specialized population. For example, replication in other geographical areas with 
different types of cancer diagnoses is needed to confirm the roles of PTSD and PTG 
in QOL. Second, since this study was cross-sectional, no definitive inferences can 
be made about the direction of causality between PTSD, PTG and QOL. However, 
our findings are consistent with the literature regarding the effects of traumatic stress 
on QOL and our interpretation of these findings is guided by a theoretical framework. 
Still, longitudinal studies are needed to establish and support evidence of causality. 
Finally, despite our finding of adequate model fit, other theoretical frameworks may 
yield equivalent or better fit and could be considered in future research studies. Of 
note, an additional model was tested (a revision of Model A’ without the social/family 
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QOL domain) which yielded a good fit, RMSEA =.050, CFI=.938, TLI=.932. This 
would suggest that alternative measures of QOL be considered in replication 
studies. 
Despite these limitations, our findings indicate that PTSD and PTG mediate 
the relationship between risk factors and QOL. The conceptual model of QOL 
among cancer survivors accounted for a large amount of variance in the survivors’ 
QOL. In addition, several demographic, clinical, health status, and psychosocial 
variables were identified that either directly or indirectly through PTSD and/or PTG 
relate to QOL. Treatments that target PTSD symptom reduction and PTG 
enhancement may assist individuals in improving their QOL along the survivorship 
trajectory.   
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Table 3.1. Characteristics of the Study Sample and Bivariate Associations with QOL 
(N=830) 
 
Demographics N % 
QOL a 
Mean or 
Correl. 
SD P-value b 
Gender      
Male 418 50.3 85.5 16.9 .917 
Female 412  49.7 85.6 16.6  
Race                       
Caucasian    718  86.5 86.3 16.3 .002 
Non-Caucasian c   112 13.5 80.5 18.7  
Ethnicity      
Hispanic 13  1.6 85.5 16.8 .986 
Non-Hispanic 817 98.4 85.5 16.8  
Income level    r = .225  <.001 
< $30,000 205  27.3 79.0 19.5 ref<.001 
$30,000 - $59,999 229  30.5 86.1 16.5 <.001 
$60,000 - $89,999 136  18.1 86.9 14.7 <.001 
≥ $90,000 181  24.1 90.0 13.7 <.001 
Education    r = .115  <.001 
High school or less 228 27.8 82.3 18.2 <.001 
Some college or trade school 263  32.1 84.9 17.7 .014 
College or post-grad 328  40.1 88.3 14.4 ref<.001 
Marital status       
Married 618  74.6 86.5 16.4 .005 
Not married d  210 25.4 82.7 17.5  
Employment status       
Employed 334 40.7  87.6 15.7 .005 
Not employed e 487  59.3  84.3 17.3  
Age at enrollment: mean (SD) 62.8  (13.3) r = .099  .054 
25-49 149 18.0 83.4 20.0 ref.001 
50-64 303 36.5 83.4 16.7 .984 
65-79 294  35.4 87.9 15.4 .016 
≥80 84 10.1 88.7 13.9 .020 
Clinical Characteristics       
NHL histology                                       
Indolent 414  52.7 84.8 17.3 .097 
Aggressive 372 47.3 86.8 16.1  
NHL stage at diagnosis   r = .-.077  .038 
Stage I 228 31.6 87.8 15.4 ref<.202 
Stage II 149 20.6 86.2 15.4 .335 
Stage III 145 20.1 84.9 18.5 .101 
Stage IV 200 27.7 84.7 17.3 .049 
Sum of treatment types: mean (SD) 2.1  (1.1) r = -.153  <.001 
Current treatment status       
Not in treatment 711 86.6 86.7 16.3 <.001 
Receiving treatment    110 13.4 78.6 18.3  
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NOTE: Not all variables represent n=830 cases due to missing data; range, 722-830. 
a
 Quality of life as measured by the Functional Assessment of Cancer Therapy – 
General Version (FACT-G). 
b
 P-values shown as superscripts are for the overall F-test for the categorical 
variable with k-1 degrees of freedom where k is the number of categories.  
c
 African-American, American Indian/Alaskan, Asian, and multiple races.  
d
 Widowed, separated, divorced, and single. 
e Unemployed and retired. 
Abbreviations: SD, standard deviation; UNC, University of North Carolina 
NHL disease status       
In remission or cured  648 78.0 87.8 15.0 <.001 
Not in remission  102 12.3 75.2 20.0  
Number of NHL recurrences       
0 534 65.9 86.9 16.3 .003 
≥1 276 34.1 83.2 17.4  
Frequency of NHL-related exams     r = -.234  <.001 
Age at diagnosis: mean (SD) 52.4  (14.1) r = .038  .279 
Range:  19-87     
Years since diagnosis: mean (SD) 10.4  (7.3) r = .108  .002 
2-4 yrs 202 24.4 84.5 17.1 ref.010 
5-9 yrs 307 37.0 84.6 17.4 .909 
10-14 yrs 143 17.1 85.0 15.9 .772 
15-19 yrs 85 10.3 85.8 17.1 .533 
≥20 yrs 93 11.2 91.4 13.9 <.001 
Health Status      
Secondary cancer        
Yes 113 13.7 83.8 15.8 .205 
No 711 86.3 85.9 16.8  
Co-morbidities: mean (SD)        2.9 (2.2) r = -.387  <.001 
Years since last physical exam     r = -.119  .001 
Psychosocial      
Social support: mean (SD) 83.3  (16.3) r = .490  <.001 
Range: 20-100     
Appraisal of life threat and  
treatment intensity: mean (SD) 19.4  (5.9) 
r = -.285  <.001 
Range: 6-30     
Employment and insurance issues 
related to cancer: mean (SD) 1.1  (2.1) r = -.280  <.001 
Range: 0-17     
Psychological Effects      
PTSD symptom clusters: mean (SD) 0.6 0.9 r = -.621  <.001 
Range: 0-3     
Post-traumatic growth: mean (SD) 60.4 24.6 r = .133  <.001 
Range: 0-105     
Table 3.2. Correlation Matrix 
 
Demographics Range M SD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
1. Some college   0,1 0.33 0.47                       
2. College degree  0,1 0.40 0.49 -0.56                      
3. Not employed  0,1 0.60 0.49 0.07 -0.21                     
4. Age  25-92 62.79 13.32 0.02 -0.15 0.55                    
Clinical 
      
        
  
         
5. Active disease  0,1 0.15 0.35 0.03 0.01 -0.02 -0.01                   
6. Frequency of exams   7.35 8.29 0.07 -0.04 0.11 -0.05 0.35                  
7. Yrs since diagnosis  2-44 10.42 7.25 -0.03 -0.04 0.04 0.16 -0.12 -0.24                 
Health Status 
                         
8. Co-morbidity  0-30 5.60 4.89 0.05 -0.16 0.27 0.25 0.05 0.06 0.08                
Psychosocial 
                         
9. MOS-SSS a 20-100 83.28 16.32 -0.05 0.01 0.04 0.05 -0.05 0.00 -0.00 -0.19               
10. ALTTIQ b 6-30 19.37 5.98 -0.06 -0.07 -0.01 -0.18 -0.02 0.16 0.02 0.01 0.00              
11. CALGB c 0-17 1.09 2.13 -0.01 0.03 -0.16 -0.25 0.06 0.07 0.05 0.11 -0.23 0.20             
PTSD Symptom d 
      
 
                  
12. Re-experiencing  0,1 0.19 0.39 -0.08 -0.16 -0.06 -0.22 0.16 0.17 -0.10 0.09 -0.18 0.45 0.24            
13. Avoidance  0,1 0.14 0.34 0.02 -0.08 0.11 -0.05 0.14 0.19 -0.17 0.32 -0.33 0.32 0.23 0.71           
14. Arousal  0,1 0.30 0.46 0.04 -0.12 0.05 -0.11 0.09 0.09 -0.12 0.32 -0.27 0.27 0.24 0.55 0.73          
PTGI e 
                         
15. Relating to others 0-35 21.75 8.64 -0.01 -0.15 0.04 -0.01 -0.14 -0.02 0.03 0.00 0.29 0.22 -0.01 0.11 -0.08 0.03         
16. New possibilities 0-25 10.94 6.44 -0.02 -0.11 -0.06 -0.15 -0.10 -0.06 0.09 0.01 0.16 0.22 0.09 0.18 0.01 0.04 0.79        
17. Personal strength 0-20 11.80 5.15 0.05 -0.14 -0.01 -0.05 -0.12 -0.03 0.10 0.00 0.18 0.22 0.03 0.13 -0.07 0.04 0.82 0.80       
18. Spiritual change 0-10 6.21 3.35 -0.01 -0.19 0.04 -0.04 -0.12 -0.04 0.08 0.07 0.15 0.23 0.04 0.19 -0.03 0.06 0.70 0.67 0.67      
19. Appreciation for life 0-15 9.72 3.81 -0.01 -0.11 -0.06 -0.17 -0.09 0.03 0.02 -0.03 0.14 0.32 0.08 0.25 0.01 0.04 0.74 0.73 0.73 0.66     
FACT-G f 
                         
20. Physical 0-28 22.81 5.57 -0.07 0.21 -0.16 0.04 -0.23 -0.26 0.11 -0.40 0.27 -0.34 -0.23 -0.42 -0.56 -0.49 -0.03 -0.03 -0.02 -0.10 -0.06    
21. Emotional 0-24 19.63 4.14 -0.00 0.08 -0.02 0.15 -0.22 -0.24 0.14 -0.25 0.33 -0.33 -0.20 -0.51 -0.65 -0.53 0.06 0.04 0.08 0.04 -0.02 0.60   
22. Functional 0-28 20.77 6.06 -0.03 0.15 -0.17 0.01 -0.22 -0.22 0.09 -0.42 0.40 -0.22 -0.23 -0.40 -0.60 -0.52 0.14 0.15 0.17 0.07 0.10 0.69 0.63  
23. Social/Family 0-28 22.33 5.00 0.03 -0.03 0.07 0.15 -0.14 -0.06 0.01 -0.14 0.58 -0.07 -0.23 -0.24 -0.45 -0.34 0.33 0.21 0.24 0.20 0.19 0.31 0.46 0.49 
                          
 
NOTE: Analyses conducted with imputed data for independent variables; r ≥  |.07|, p< .05; r ≥  |.09|, p< .01; r ≥  |.12|, p< .001. 
a Medical Outcomes Study – Social Support Survey total score. 
b Appraisal of Life Threat and Treatment Intensity Questionnaire total score. 
c Cancer and Leukemia Group B instrument to assess employment and insurance-related situations and difficulties. 
d Based on the PTSD Checklist (PCL-C). Means and standard deviations for PTSD Symptom categorical indicators are not 
equivalent to the values used in MPLUS weighted least square means and variance adjusted parameter estimation technique. 
e Post-traumatic Growth Inventory. 
f Functional Assessment of Cancer Therapy – General Version, a measure of quality of life. 
Abbreviations: M, mean; SD, standard deviation
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Table 3.3. Summary of Goodness-of-Fit Statistics for Comparative Models of QOL 
Comparison 
Models Description RMSEA CFI TLI 
A Partial mediation .083 .827 .824 
B No mediation .104 .722 .723 
C Full mediation .084 .798 .818 
A´ Trimmed Model A  .072 .868 .865 
           
Note: Analyses conducted with imputed data. 
Abbreviations: RMSEA, root mean square error of approximation; CFI, comparative 
fit index; TLI, Tucker-Lewis Index. 
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Table 3.4. Weighted Least Square Means and Variance Adjusted Parameter 
Estimates for the Final Model 
 
Parameter Estimate SE P-value 
Direct effects 
PTGI → QOL 0.068 0.014   <.001 
PTSDSX → QOL -2.649    0.246    <.001 
ACTIVE DISEASE → PTGI -2.140    0.799     .007 
STUDY AGE → PTGI -0.066    0.025     .009  
SOME COLLEGE → PTGI -1.187    0.708     .094  
COLLEGE → PTGI -3.087    0.680     <.001 
ALTTIQ → PTGI 0.321    0.045      <.001 
MOS-SSS → PTGI 0.110    0.016      <.001 
SOME COLLEGE → PTSDSX -0.121    0.090     .178 
COLLEGE → PTSDSX -0.199    0.090     .027  
ALTTIQ → PTSDSX 0.048 0.007 <.001 
MOS-SSS → PTSDSX -0.012 0.002 <.001 
SCQ → PTSDSX 0.041 0.007 <.001 
YEARS SINCE DIAGNOSIS → PTSDSX -0.019 0.005 <.001 
CALGB → PTSDSX 0.052 0.015 <.001 
ACTIVE DISEASE → QOL -1.788 0.315 <.001 
STUDY AGE → QOL 0.046    0.010      <.001 
SOME COLLEGE → QOL 0.400 0.241 .097 
COLLEGE → QOL 0.612 0.265 .021 
ALTTIQ → QOL -0.045 0.020 .022 
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Abbreviations: PTGI, Post-traumatic Growth Inventory; QOL, quality of life; PTSDSX, 
Post-traumatic Stress Disorder symptoms; ALTTIQ, Appraisal of Life Threat and 
Treatment Intensity Questionnaire; MOS-SSS, Medical Outcomes Study - Social 
Support Survey; CALGB, Cancer and Leukemia Group B questionnaire to assess 
cancer-related employment and insurance issues; SCQ, Self-administered Co-
morbidity Questionnaire. 
MOS-SSS → QOL 0.056 0.007 <.001 
NOT EMPLOYED → QOL -0.836 0.255 .001 
FREQUENCY OF EXAMS → QOL -0.047 0.014 <.001 
SCQ → QOL -0.122 0.020 <.001 
Factor Loadings 
PTGI → RELATING TO OTHERS 1.000 0.000  
PTGI → NEW POSSIBILITIES 0.726 0.027 <.001 
PTGI → PERSONAL STRENGTH 0.593 0.020 <.001 
PTGI → SPIRITUAL CHANGE 0.327   0.016     <.001 
PTGI → APPRECIATION FOR LIFE 0.403 0.015     <.001 
PTSDSX → RE-EXPERIENCING 1.000 0.000   
PTSDSX → AVOIDANCE 1.471    0.111     <.001 
PTSDSX → AROUSAL 1.077    0.088     <.001 
QOL → PHYSICAL 1.000 0.000   
QOL → EMOTIONAL 0.927    0.047     <.001 
QOL → FUNCTIONAL 1.413    0.070     <.001 
QOL → SOCIAL/FAMILY 0.830    0.059     <.001 
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Figure 3.1. Conceptual Model of QOL among Cancer Survivors 
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Figure 3.2. The Final Model 
 
Note: Weighted least squares estimates for each path are significant at the P<.05 
level; non-significant paths are excluded. Analyses conducted with imputed data. 
Abbreviations: PTSD, Post-traumatic Stress Disorder; RMSEA, root mean square 
error of approximation; CFI, comparative fit index; TLI, Tucker-Lewis Index; R2, 
proportion of variance in the dependent variable that can be predicted from the 
independent variables; QOL, quality of life; PTSDSX, PTSD symptoms; PTGI, Post-
traumatic Growth Inventory 
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 INTRODUCTION 
 Overall, a growing body of evidence suggests that long-term survivors who were 
diagnosed and treated for one of the more common forms of adult cancer report 
similar quality of life (QOL) to that of the general population.1-4 However, specific 
areas of unresolved concern have been identified in this population, including sexual 
dysfunction,3,5,6 low energy level and fatigue,1,7,8 and psychological distress.9-12 
Conversely, several studies have demonstrated positive outcomes associated with 
having cancer, such as greater appreciation for life, closer personal relationships, 
and deeper spiritual understanding.6,13,14 
 Yet, less is known about the QOL of survivors of adult non-Hodgkin’s lymphoma 
(NHL), the sixth most common cancer in the US with an individual lifetime risk of 1 in 
50. NHL is a heterogeneous group of cancers of the lymphatic system with an 
overall 5-year survival rate of 50-60%; statistics vary depending on the cell type, 
stage of disease at the time of diagnosis, and treatment. Indolent lymphomas 
generally carry a good prognosis with a median survival of 10 years but also a high 
rate of relapse, and are usually not curable in advance stages. Treatment plans for 
the indolent forms include periods of watchful waiting, radiation therapy and 
chemotherapy. By comparison, many individuals who convert to or present with 
aggressive forms of NHL can be cured (30-60%) with intensive chemotherapy 
regimens but the disease has a shorter natural history, with the greatest risk of 
relapse within 2 years of treatment cessation.15 
The incidence rates of NHL have doubled since the early 1970’s, partly 
because of AIDS-related NHL and improved methods of diagnosis. Over the next 
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few years, the increasing average age of the American population together with the 
growing number of medical advances are expected to add to the incidence rates of 
NHL.16 Consequently, and since the number of cancer survivors in the US is rapidly 
increasing, health care teams would benefit from evidence regarding the needs of 
this population so that interventions can be designed to improve their overall 
functioning and QOL, if indicated. Therefore, the primary purpose of this paper is to 
develop a QOL profile of this heterogeneous group of survivors of adult NHL, 
including a comparison between those who have active disease and those in 
remission or cured.   
While the majority of survivorship research is conducted with disease-free 
survivors who are ≥5 years post-diagnosis (LTS),1,3,4,7 this paper also examines the 
QOL of those who have active NHL disease and are short-term survivors (STS; 
those 2-4 years post-diagnosis). With the increasing prevalence of survivors living 
with cancer as a chronic illness, which is especially the case with indolent 
lymphomas, our sample was divided by disease status to provide a more 
comprehensive and accurate profile of this under-studied population. Further, we 
aim to challenge the conventional 5-year cut-off mark used in survivorship studies by 
including STS in our sample and comparing their outcomes to those who are further 
out from diagnosis (i.e., LTS). Finally, due to the limited number of instruments 
designed for use with LTS, we included three separate outcome measures to 
capture many of the different components of QOL in our cancer sample. Given the 
recent advances in cancer therapies (e.g. rituximab, interferon) with the associated 
transition of cancer to a chronic illness with alternating periods of disease and 
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remission as is increasingly the case with NHL, this paper provides a window into 
the diverse needs of cancer survivors across the recovery trajectory.  
METHODS 
Participants and Procedures 
Potential study participants were identified through the Duke and University of North 
Carolina (UNC) Lineberger Comprehensive Cancer Center Tumor Registries and 
contacted by mail following physician approval. Individuals were eligible for this 
study if they were diagnosed with adult (≥19 years old) NHL and were at least 2 
years post-diagnosis. Prospective participants were sent an introductory letter 
signed by their physician, a self-administered questionnaire, a $2 bill incentive, and 
thank-you/reminder postcards. Non-respondents were sent replacement mailings 
and followed up by telephone to confirm receipt of the survey packet. Approval for all 
procedures was granted by the Institutional Review Boards at the University of North 
Carolina and Duke Schools of Medicine. 
Measures 
The demographic, clinical, health status, psychosocial and psychological effect 
variables chosen for inclusion in this study are taken from a conceptual model which 
is theoretically and empirically-based. Information processing17,18 and stress, coping, 
and adaptation theories19,20 form the base of the model to which characteristics 
associated with cancer-related QOL, Post-traumatic Stress Disorder (PTSD), and 
post-traumatic growth (PTG) were added.3,12,21  
Demographic and Clinical Characteristics 
Demographic and clinical information such as race, marital status, income, 
education, and disease status was collected via self-report. The Tumor Registry 
databases were used to obtain details regarding diagnosis (e.g., date, histology) and 
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treatment history. NHL histology was categorized as indolent or aggressive based 
on the updated Revised European American Lymphoma/World Health Organization 
(REAL/WHO) classification system.22   
Health Status 
The Self-administered Co-morbidity Questionnaire (SCQ)23 was used to assess 
other non-NHL health-related problems, with up to 3 points for each of 12 conditions, 
depending on severity. In addition, selected questions related to healthcare use and 
secondary cancer status were adapted for use from the Childhood Cancer Survivor 
Study survey.24 
Psychosocial 
The 20-item Medical Outcomes Study-Social Support Survey (MOS-SSS) was used 
to measure the perceived availability of social support,25 with scores ranging from 
20-100 (α=.97 in this study).  The Appraisal of Life Threat and Treatment Intensity 
Questionnaire (ALTTIQ; six items, range 6-30; α=.80) was used to assess the extent 
to which cancer and its treatment are perceived to be life-threatening and intense.26 
Finally, to assess employment and insurance-related situations and difficulties, 24 
questions (possible range 0-24, α=.82) were derived from an instrument developed 
by the Cancer and Leukemia Group B (CALGB) clinical research group.27 
Psychological Effects 
The PTSD Checklist-Civilian Version (PCL-C) assesses symptomatology in non-
combat populations by presenting a self-report symptom checklist that closely 
mirrors criteria set forth by the DSM-IV for a formal diagnosis of PTSD.28,29 The 
instructions were modified for the current study to focus on the particular traumatic 
stressor of interest; specifically, survivors were asked to rate each PTSD symptom in 
the past 4 weeks with respect to their diagnosis and treatment for lymphoma. The 
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continuous scoring method was used, and the three domains and summary 
demonstrated good reliability: re-experiencing (α=.88); avoidance (α=.82); arousal 
(α=.78); and total score (α=.91). The Post-traumatic Growth Inventory (PTGI) is a 
21-item scale that was used to measure positive life changes following a cancer-
related trauma.18 The overall α=.96, with the five domains showing strong internal 
consistency: relating to others (α=.92); new possibilities (α=.88); personal strength 
(α=.86); spiritual change (α=.89); and appreciation of life (α=.80).  
Quality of Life 
Three measures were used to assess QOL in this sample. First, a general health 
outcome measure was used to allow for comparisons to general population-based 
norms; the Medical Outcomes Study- Short Form (SF-36) is comprised of 36 items 
representing eight sub-scales and two summary scores, the physical health 
summary (PCS) and the mental health summary (MCS).30 The internal consistency 
reliability estimates for the 8 domains ranged from .84 to .95 in the present study. 
Second, in an effort to capture the more unique issues of cancer patients, the 
Functional Assessment of Cancer Therapy – Lymphoma Version (FACT-LYM) was 
used, which is a 27-item general self-report measure (FACT-G) with an additional 15 
items to assess NHL-related symptoms.31 The FACT-G was originally intended to be 
used to assess QOL in individuals receiving cancer treatment, but is increasingly 
being used with disease-free samples as well. The internal consistency reliability in 
our sample was excellent: physical well-being (α=.87); emotional well-being (α=.77); 
functional well-being (α=.88); social/family well-being (α=.80); FACT-G total score 
(α=.93); and additional concerns (α=.92).  Third, the Impact of Cancer (IOC) is a new 
instrument that measures certain aspects of long-term survivorship that are not 
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currently measured by existing tools (e.g., health worries, meaning of cancer). The 
IOC was tested on 193 long-term survivors of breast, prostate, colorectal cancers, 
and lymphoma in combination with other well-established measures (SF-36, Quality 
of Life-Cancer Survivors). A factor analysis of 81 items using the a priori QOL 
domains yielded ten specific subscales for the IOC instrument, with internal 
consistency estimates ranging from .67 to .89.32 Reliability estimates from our study 
were similar for the two IOC summary scales and their corresponding sub-scales: 1) 
higher order positive impact summary (α=.91), positive outlook (α=.73), health 
awareness (α=.69), positive self-evaluation (α=.86), value of relationships (α=.62), 
meaning of cancer (α=.67); and 2) higher order negative impact summary (α=.90),  
negative outlook (α=.79), body changes (α=.78), health worry (α=.81), negative self-
evaluation (α=.66), and life interferences (α=.76). Higher scores on all of these QOL 
outcome measures indicate better QOL, except for the IOC higher order negative 
impact scale, where lower scores indicate better QOL. 
Statistical Methods 
Descriptive statistics were used to estimate the means and develop a QOL profile for 
this population, overall and by survivorship status (active disease, STS, LTS). Also, 
χ
2
, ANOVA and t-tests were used to compare distributions and mean levels of 
demographic, clinical, health status, psychosocial and psychological effect measures 
across the three survivorship groups.  Multiple linear regression analyses were 
performed for the SF-36 PCS and MCS, FACT-G, FACT-LYM additional concerns 
and IOC higher order positive and negative impact scales in order to examine the 
association between survivorship status and QOL, adjusting for demographic, 
clinical, health status, psychosocial and psychological effect characteristics. For all 
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comparisons, individuals with active disease were the reference group; however, 
because disease status was missing for n=97 individuals, these survivors were 
excluded from further analyses. For each of the five outcomes, sequential series of 
linear regression models were constructed to examine the association of active 
disease with QOL. Six models were constructed for each of the five QOL measures, 
sequentially adding each domain of covariates. For example, the first model tested 
for the effect of active disease vs. STS and LTS on QOL without adjusting for 
covariates while the sixth (final) model included all of the covariates from the five 
domains. Statistical analysis was carried out using SPSS V14.0 software. 
RESULTS 
 
For the 1312 eligible survivors who were mailed a survey, 117 packages were 
returned undelivered and tracing attempts were unsuccessful. Among the remaining 
1195 survivors who were assumed to have received their survey, 886 (74.1%) 
completed and returned the survey. Sample bias was tested between those who did 
and did not participate using data obtained through the tumor registries. Survivors 
who participated were older at diagnosis (52.6 years vs. 48.1, p<.001), older at study 
enrollment (62.9 years vs. 58.8 years, p<.001), and less frequently African-American 
(10% vs. 20%, p<.001). Slightly more females than males participated, 86% were 
Caucasian, and almost half (46%) were at least 65 years of age at enrollment.  
 Table 4.1 lists the information collected via self-report and the tumor registry 
databases by total sample and survivorship status. Consistent with other 
survivorship studies, this sample had a mean number of 10.2 (7.1) years post-
diagnosis. Study participants reported an average of 2.9 co-morbid conditions (SD, 
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2.1; range, 0 to 12). Eleven percent reported no co-morbid conditions, 38% reported 
one or two conditions, 31% reported three or four conditions and 20% reported five 
or more conditions. Conditions that survivors reported receiving current treatment for 
include high blood pressure (34%), heart disease (17%), back pain (15%), and 
osteoarthritis (15%). Fourteen percent of survivors had a history of other non-skin 
cancers, including prostate (n=22), breast (n=18), melanoma (n=9), colon (n=8) and 
bladder (n=8). Twenty-four percent reported having been diagnosed with depression 
in the past, and 13% were currently being treated for it. 
 Survivors who reported having active NHL disease had a mean number of 8.1 
(5.1) years post-diagnosis and were more likely to have been diagnosed with an 
indolent lymphoma, received biologic therapy, be currently in treatment, had more 
NHL recurrences and PTSD symptoms, and less PTG than disease-free survivors. 
In addition, those with active disease were older, had less education, and were more 
likely to have received radiation and been diagnosed with a secondary cancer than 
STS. Compared to LTS, those with active disease were more likely to be college 
educated, were less likely to have received radiation therapy, and were older at 
diagnosis. 
 Figure 4.1 displays the means and standard deviations for the QOL outcomes. 
Those with active disease had poorer QOL than both STS and LTS on each of the 
six summary measures (P<.01).  For example, the mean(SD) PCS score was 
41.1(11.9) for active disease, compared to 47.0(10.5) and 45.7(10.8) for STS and 
LTS respectively, and the mean(SD) MCS score was 45.1(11.4) for active disease, 
compared to 50.0(10.1) and 49.4(11.1) for STS and LTS respectively (all at P<.001). 
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By contrast, no statistically significant differences were found in any of the six 
summary measures between STS and LTS, and in fact mean differences were no 
greater than 5% on any measure. Only on two specific subscale measures did LTS 
have lower mean scores than STS [PCS, bodily pain 50.0(10.5) vs. 52.0(9.8), P<.05; 
and IOC, meaning of cancer 14.5(4.6) vs. 15.4(4.6), P<.05].   
 Tables 4.2 and 4.3 show the regression coefficients for the effects of survivorship 
status on change in QOL as measured by the FACT-G, IOC, and SF-36 summary 
scores. The coefficients for the series of six sequential models represent the 
increase in the mean level of QOL attributable to disease-free survivorship status, 
after adjusting for the covariates in the model. Consistent with bivariate analyses, 
Model I indicates that disease-free survivorship status had a strong relationship to 
better QOL scores (all at P<.05). For all models, there was a graded effect with STS 
experiencing better QOL than LTS. The adjustment for each domain of covariates 
reduced the magnitude of the survivorship status effect slightly but remained 
statistically significant, except for the IOC Negative Impact and SF-36 summary 
scales, where the effects became non-significant after adjustment for demographic, 
clinical, health status, psychosocial and psychological effect characteristics. Finally, 
a sizable amount of the variance was explained by the models; for example, 68% of 
the variance in the cancer-specific FACT-G was explained by the covariates. 
DISCUSSION 
This study provides one of the first examinations of QOL among NHL survivors 
overall and by survivorship status. As demonstrated by these findings, NHL 
survivors are a diverse group with varying levels of QOL. Unexpectedly, no 
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significant differences were found between STS and LTS on any of the QOL 
measures, which brings into question the convention of using a 5-year post-
diagnosis cut-point in long-term survivorship studies. Additional findings included a 
strong independent relationship between survivorship status (active disease vs. STS 
and LTS) and QOL, which was demonstrated for all QOL measures. In addition, 
after controlling for all covariates, there was still a significant difference between 
individuals with active disease and those who were disease-free in the FACT-G and 
IOC Positive Impact summary scales. This finding implies that there remain 
unidentified characteristics that relate to QOL and differ between those with active 
disease and those who are disease-free, even in light of large R2 values (FACT-G, 
.68; IOC Positive, .65). However, the effects of survivorship status became non-
significant in the general QOL measure (SF-36) and IOC Negative Impact summary 
score, which implies that differences in these QOL measures based on disease 
status are essentially explained by associated differences in some of the covariates.  
A possible explanation for the unexplained characteristics between those with 
active disease and disease-free survivors after adjusting for all of the covariates is 
that the FACT-G, a cancer-specific measure, may not measure depression and 
anxiety symptomatology and physical limitations as thoroughly as the SF-36, which 
is of some concern. In addition, the IOC was specifically designed for long-term 
survivors; therefore, the Positive Impact summary may not be assessing for certain 
outcomes associated with active disease. Across most QOL measures there was 
evidence of a mediation effect, where the inclusion of the psychological effect 
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covariates (PTSD, PTG) produced the largest proportional drops in the survivorship 
status estimates.  
When compared to general population-based norms for the SF-36 PCS and MCS 
(mean=50, SD=10),33 individuals with active disease scored far lower in both 
physical (mean=41.0, SD=11.9) and mental (mean=45.4, SD=11.5) health.  As 
expected, disease-free survivors fared better, but still seemed to have worse 
physical health (STS, mean=47.2, SD=10.5; LTS, mean=45.7, SD=10.8) than the 
general adult population.33 However, after comparing our disease-free sample with 
their corresponding age-stratified normed groupings (25-34, 35-44, 45-54, 55-64, 65-
74, ≥75), our sample scored comparably (within ±1.0 point on the PCS). In 
comparisons to other cancer samples, PCS scores from our disease-free survivors 
were similar to those from another similarly-aged NHL sample,34 worse than those 
from a younger sample of breast cancer LTS,3 but better than those reported by 
older LTS of lung and colorectal cancer.1,2 Regarding mental health, scores from our 
disease-free survivors on the MCS (STS, mean=50.0, SD=10.1; LTS, mean=49.3, 
SD=11.3) were close to those from the general population;33 however, our sample 
scored lower (≤4.1 points) on the MCS than the corresponding age-stratified groups 
(except for 35-44 and ≥75), with the largest difference between the 25-34 age 
groups.33 Also somewhat disconcerting, our disease-free sample scored consistently 
worse (1.9-4.0 points lower) on the MCS than other survivors from identified LTS 
studies that used the SF-36.1-4 When considering cancer-related QOL, our disease-
free sample scored comparably on the FACT-G to other NHL survivors,35 but worse 
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in physical and functional well-being in comparisons to younger lymphedema-free 
breast and bladder cancer LTS,5,36 which may be an age effect.  
The present study was not designed to determine the mechanisms linking 
survivorship status and QOL. Most likely, however, active disease contributes to 
worse QOL through the increase in emotional and physical stress that is associated 
with the disease and treatment-related effects. For example, the largest percentage 
decrease in the coefficient estimates from the FACT-G, IOC Positive and Negative 
Impact, and MCS multiple linear regression models occurs when the psychological 
effect covariates (PTSD, PTG) are added. Furthermore, adding clinical covariates to 
the PCS model produces the largest percentage decrease in the coefficient 
estimate.  
The impact of having active disease on self-reported QOL has important 
implications. For example, health care professionals may want to pay closer 
attention to survivors with chronic (active) disease and screen for QOL-related 
problems. In addition, psychosocial intervention design and development should 
consider balancing treatment and control groups based on disease status. For 
example, individuals with active disease may be more likely to report worse QOL at 
baseline and may respond differently to specific treatment components than those 
who are disease-free. Furthermore, our data suggest that a distinguishing 
characteristic of NHL (alternating between periods of disease and remission) might 
lead to detriments in mental health, as demonstrated by lower MCS scores when 
compared to other cancer samples that are not characterized as such. Finally, 
multiple risk factors related to psychosocial (less social support, negative appraisals, 
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more cancer-related insurance and employment-related issues) and psychological 
effects (PTSD, PTG), were shown to have an effect on QOL and are potentially 
modifiable.  
There are several limitations in this study. As is typical for any cross-sectional 
study, we can not establish a cause-effect relationship between survivorship status 
and QOL. For example, we cannot ensure that the risk factor (active disease) 
preceded the outcome (QOL) due to the inability to assess this cohort over time, as 
is possible in a longitudinal design. Further, the sequential models adjusted for 
many, although likely not all, of the characteristics that might have confounded the 
relationship between survivorship status and QOL. In addition, the inclusion of 
patients from only two large comprehensive cancer centers in NC may limit the 
generalizability of our results to survivors living in other regions and treated at 
smaller hospitals. However, our demographic profile closely mirrors that of the 
national population of NHL survivors, thereby strengthening the robustness and 
generalizability of our analyses. Finally, without a matched comparison group based 
on socio-demographic and co-morbid conditions it is difficult to determine if these 
NHL survivors had better or worse QOL than a similar group of people who never 
had NHL. However, the results of comparisons to general population norms and LTS 
studies support the need to address QOL concerns in this population, as evidenced 
by lower PCS and MCS scores in our sample.  
In summary, the use of general health and cancer-specific QOL measures 
revealed significant differences between NHL survivors who reported having active 
disease and those who were disease-free. In addition, there were no significant 
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differences in QOL between STS and LTS, which challenges the current use of the 
5-year mark in long-term survivorship research. The data from this study illustrate 
the value of using multiple instruments that assess areas that are particularly 
relevant to cancer survivors and of studying subgroups of survivors with differing 
disease status.  
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Table 4.1. Characteristics of the Study Sample 
 
 
All survivors 
N= 886 
 Active 
disease 
n=109 
 Short-term 
survivor 
n=159 
 Long-term 
survivor 
n=521 
 
Demographics N % 
 
N % 
 
N % 
 
N % P-value 
Gender             
Male 435  49.1  54 49.5  76 47.8  263 50.5 .838 
Female 451  50.9  55 50.5  83 52.2  258 49.5  
Race                              
Caucasian    758  85.5  88 80.7  140 88.0  455 87.3 .111 
African-American   91  10.3  15 13.8  11 6.9  44 8.5  
Multiple race 30  3.4  5 4.6  6 3.8  17 3.3  
Other  7  .8  1 0.9  2 1.3  5 0.9  
Ethnicity              
Non-Hispanic 873  98.5  107 98.2  157 98.7  513   98.5 .930 
Hispanic 13  1.5  2 1.8  2 1.3  8 1.5  
Income level              
< $30,000 225  28.4  28 28.0  34 23.6  128 27.4 .769 
$30,000 - $59,999 239  30.2  32 32.0  43 29.9  142 30.3  
$60,000 - $89,999 139  17.6  21 21.0  28 19.4  80 17.1  
≥ $90,000 189  23.8  19 19.0  39 27.1  118 25.2  
Education              
High school or less  250  28.9  29 27.6  28 17.7  158 30.8 .031 
Some college or trade school 277  32.1  31 27.5  58 36.7  157 30.6  
College or post-grad 337 39.0  45 47.9  72 45.6  198 38.6  
Marital status              
Married 648  73.9  81 75.0  126 79.3  387  74.4 .462 
Not married d  229 26.1  27 25.0  33 20.7  133 25.6  
Employment status              
Unemployed  46 5.3  6 5.6  9 5.7  23 4.5 .545 
Retired 477 54.6  63 58.3  78 49.7  291 56.5  
Employed 350 40.1  39 36.1  70 44.6  201 39.0  
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All survivors 
N= 886 
 Active 
disease 
n=109 
 Short-term 
survivor 
n=159 
 Long-term 
survivor 
n=521 
 
 
N %  N %  N %  N % P-value 
Age at enrollment: mean (SD) 62.9 (13.5)  62.7 (12.6)  59.7 (14.1)  63.7 (13.1) .005 
25-49 157 17.7  20 18.3  40 25.2  80 15.4 .122 
50-64 323 36.5  44 40.4  57 35.8  189 36.3  
65-79 315  35.6  34 31.2  48 30.2  197 37.8  
≥80 91 10.2  11 10.1  14 8.8  55 10.5  
Clinical Characteristics              
NHL histology                                 
Indolent 445  53.2  85 81.0   66  44.0  232 47.3 <.001 
Aggressive 391 46.8  20 19.0   84 56.0  259 52.7  
NHL stage at diagnosis             
Stage I 247 32.2  29 34.1  42  29.6  145 31.2 .300 
Stage II 159 20.8  10 11.7  32 22.5  103 22.1  
Stage III 146 19.1  23 27.1  26 18.3  86 18.5  
Stage IV 214 27.9  23 27.1  42 29.6  131 28.2  
Sum of treatment types: mean (SD) 2.1 (1.1)  2.4 (1.3)  2.2 (1.1)  2.1 (1.0) .013 
Surgery 248 28.0   25  22.9  48 30.2  162 31.1 .256 
Radiation 418 47.2  48 44.0  65 40.9  268 51.4 .042 
Chemotherapy 692 78.1  83 76.2  124 78.0  428 82.2 .240 
Bone marrow/stem cell transplant 132 14.9  16 14.7  29 18.2  79 15.2 .615 
Biologic therapy 261 29.5  60 55.1  65 40.9  110 21.1 <.001 
Current treatment status              
Not in treatment 752  86.5  38  35.5  149 94.3  499 96.3 <.001 
Receiving treatment    117  13.5  69 64.5  9 5.7  19 3.7  
Number of NHL recurrences              
0 562 65.7  51  47.7  121 76.6  349 67.9 <.001 
≥1 293 34.3  56 52.3  37 23.4  165 32.1  
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Note: Individuals without a disease status classification (n=97) are included in the total sample (n=886) but excluded 
from further analysis. The active disease group represents individuals who self-reported having current NHL disease; 
 All survivors 
N= 886 
 Active 
disease 
n=109 
 Short-term 
survivor 
n=159 
 
Long-term 
survivor 
n=521 
 
 
N %  N %  N %  N  % P-value 
Age at diagnosis: mean (SD) 52.6 (14.2)  54.5 (13.2)  55.9 (14.2)  50.8 (14.0) <.001 
Range: 19-87  20-82  22-87  19-82  
Years since diagnosis: mean (SD) 10.2 (7.1)  8.1 (5.1)  3.8 (0.7)  12.9 (7.4) <.001 
2-4 yrs 219 24.7  32 29.4  109 100.0     
5-9 yrs 335 37.8  48 44.0     247 47.4  
10-14 yrs 150 16.9  19 17.4     113 21.7  
15-19 yrs 88 9.9  6 5.5     75 14.4  
≥20 yrs 94 10.6  4 3.7     86 16.5  
Health Status            
Secondary cancer              
Yes 120 13.5  16  14.8  12 7.6  81 15.6 .035 
No 752 84.9  92 85.2  147 92.4  439 84.4  
Co-morbidities: mean (SD)        2.9 (2.1)  3.0 (2.2)  2.5 (2.1)  3.0 (2.1) .070 
Psychosocial            
Social support: mean (SD) 83.1 (16.4)  81.7 (16.1)  85.0 (15.7)  83.5 (16.2) .268 
Range: 20-100  34-100  22-100  26-100  
Appraisal of life threat and  
treatment intensity: mean (SD) 
19.3 (6.0)  19.0 (6.5)  18.8 (5.9)  19.6 (5.8) .330 
Range: 6-30  6-30  6-30  6-30  
Employment and insurance issues 
related to cancer: mean (SD) 
1.1 (2.1)  1.2 (2.2)  1.0 (2.0)  1.0 (2.0) .636 
Range: 0-17  0-12  0-11  0-17  
Psychological Effects            
PTSD symptom clusters: mean (SD) 0.6 (0.9)  0.8 (1.1)  0.6 (0.9)  0.6 (0.9) .013 
Range: 0-3  0-3  0-3  0-3  
PTSD symptoms: mean (SD) 27.0 (9.9)  30.5 (12.1)  26.3 (8.2)  26.0 (9.2) <.001 
Range: 17-78  17-71  17-55  17-78  
Post-traumatic growth: mean (SD) 60.5 (24.7)  52.0 (26.0)  61.5 (23.5)  62.3 (24.4) <.001 
Range: 0-105  0-99  0-105  0-105  
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the short-term survivor group represents individuals who are 2-4 years post-diagnosis and have reported being 
disease-free; long-term survivor group represents individuals who are at least 5 years post-diagnosis and have 
reported being disease-free.
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Table 4.2. Regression Coefficients for the Effects of Survivorship Status on Cancer-related Quality of Life (n=503) 
 
 FACT-G  IOC Positive Impact  IOC Negative Impact 
Model Covariates R2 STS vs. Active Est.  (Std error) 
LTS vs. Active 
Est. (Std error) R
2
 
STS vs. Active 
Est. (Std error) 
LTS vs. 
Active Est. 
(Std error) 
 R2 
STS vs. 
Active Est. 
(Std error) 
 
LTS vs. 
Active Est. 
(Std error) 
 
I. SS .054 11.6 (2.5) **** 10.8 (2.1) **** .024 1.64 (0.50) *** 1.38 (0.43) *** .019 -0.97 (0.41) ** -1.10 (0.35) *** 
II. SS+DEM .127 11.1 (2.4) **** 10.5 (2.1) **** .153 1.68 (0.47) **** 1.44 (0.41) *** .084 -0.97 (0.40) ** -1.10 (0.34) *** 
III. SS+DEM+CLN .173 10.7 (2.8) **** 7.9 (2.6) *** .202 1.76 (0.56) *** 1.72 (0.52) *** .201 -0.56 (0.45)  -0.21 (0.42)  
IV. SS+DEM+CLN+
HTH .290 10.2 (2.6) **** 8.7 (2.5) **** .214 1.74 (0.55) *** 1.65 (0.52) *** .256 -0.51 (0.44)  -0.30 (0.41)  
V. SS+DEM+CLN+
HTH+PSO  .494 8.6 (2.2) **** 8.5 (2.1) **** .330 1.89 (0.51) **** 1.66 (0.48) *** .405 -0.26 (0.39)  -0.29 (0.37)  
VI. SS+DEM+CLN+
HTH+PSO+ PSY  .683 4.7 (1.8) *** 3.9 (1.7) ** .648 1.10 (0.38) **** 0.80 (0.35) ** .583 0.24(0.33)  0.32 (0.31)  
  
          
    
 
 
Table 4.3. Regression Coefficients for the Effects of Survivorship Status on Health-related Quality of Life (n=503)   
 
 SF-36 Physical Component Summary  SF-36 Mental Component Summary 
Model Covariates R2 STS vs. Active  Est. (Std error) 
LTS vs. Active 
Est. (Std error) R
2    STS vs. Active 
Est. (Std error) 
LTS vs. Active 
Est. (Std error) 
I. SS .028 6.1 (1.7) **** 5.0 (1.4) *** .016 4.8 (1.7) *** 3.2 (1.5) ** 
II. SS+DEM .224 5.0 (1.5) *** 4.8 (1.3) **** .069 4.7 (1.7) *** 3.2 (1.5) ** 
III. SS+DEM+CLN .256 3.9 (1.8) ** 2.6 (1.7)  .100 4.6 (2.0) ** 2.2 (1.9)  
IV. SS+DEM+CLN+HTH .443 3.4 (1.6) ** 3.1 (1.5) ** .184 4.3 (1.9) ** 2.7 (1.8)  
V. SS+DEM+CLN+HTH+PSO  .445 3.3 (1.6) ** 3.1 (1.5) ** .306 3.5 (1.8) * 2.6 (1.7)  
VI. SS+DEM+CLN+HTH+PSO+PSY .458 2.6 (1.6)  2.3 (1.5)  .507 0.9 (1.5)  -0.5 (1.4)  
  
         
 
Abbreviations: FACT-G, Functional Assessment of Cancer Therapy-General; IOC, Impact of Cancer; SF-36, Medical Outcomes Study-Short form; STS, Short-
term disease-free survivor( <5 years) ; LTS, long-term disease-free survivor ( ≥5 years); SS = Survivorship status; DEM, demographics (gender, race, ethnicity, 
age, income, education, marital status, employment status); CLN, Clinical (histology, stage, surgery, radiation therapy, chemotherapy, bone marrow/stem cell 
transplant, biologic therapy, NHL treatment status, recurrence, number of visits to an MD for NHL, site of treatment); HTH, Health status (other diagnosed cancer 
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excluding skin, co-morbidity, time since last physical exam); PSO, Psychosocial (social support, appraisal of life threat and treatment intensity, employment and 
insurance issues); PSY, Psychological effects (Post-traumatic Stress Disorder symptoms, post-traumatic growth). 
*p<.10; **p<.05; ***p<.01; ****p<.001.
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Figure 4.1. Quality of Life in non-Hodgkin’s Lymphoma Survivors 
Note: Higher scores indicate better QOL except for the IOC Negative Impact summary; error 
bars represent 1 standard deviation from mean; all comparisons between active and 
disease-free survivors are statistically significant at P< .01; no statistical difference between 
short-term and long-term disease-free survivors (P>.05); Mean (SD) scores for the entire 
sample (n=886) are: PCS, 45.3 (11.1); MCS, 48.7 (11.2); FACT-G, 85.5 (17.0); Additional 
concerns, 47.8 (9.9); IOC Positive, 15.4 (3.3); IOC Negative, 8.0 (2.8). 
  
 
 
 
 
CHAPTER 5 
 
Conclusion 
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This dissertation study was conducted to enhance the understanding of and 
thereby improve the quality of life of cancer survivors by demonstrating findings to 
inform research and practice. While the majority of survivors did not exhibit 
symptoms of PTSD, the impact of the diagnosis and treatment for cancer persists for 
many, as evidenced by symptoms in 39% of this NHL sample. Further research into 
understanding cancer-related PTSD, such as longitudinal studies that track 
symptomatology over the survivor trajectory in a recently diagnosed cohort and 
replication efforts that test the novel conceptualization of PTSD and PTG as 
mediators (SEM analysis) with different cancer samples is needed to inform the 
design of a phased-approach intervention with considerations to the optimal timing 
for treatment delivery.  Early identification of those at risk (e.g., non-Caucasian, low 
social support) could promote screening and treatments that target PTSD symptom 
reduction and PTG enhancement to assist individuals in improving their QOL along 
the survivorship trajectory. A more detailed discussion of the implications for 
research and practice follow below.   
Implications for Research 
Several implications for cancer survivorship research have emerged following 
this dissertation study. First, despite the call for research and increasing evidence of 
the prevalence of PTSD symptomatology in cancer survivor populations, there 
remains a paucity of information concerning the natural history of PTSD 
symptomatology over the course of survivorship, including timing of onset, natural 
resolution, and specific areas of need. For example, Smith et al.1 argued that 
longitudinal research in cancer-related PTSD is important conceptually and for 
treatment purposes, and Stuber et al.2 discussed the need to examine the types of 
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intrusive thoughts and avoidant objects present at each stage of the cancer 
experience to guide selection of empirically-tested PTSD interventions. Mullan3 
describes these stages as “seasons of survivorship”, representing the acute 
(diagnosis, treatments), extended (initial treatment cessation, “watchful waiting”, 
follow-up exams, remission of disease), and permanent (cure) phases of 
survivorship.   
Empirical data suggest that PTSD symptoms may increase and decrease over 
time (re-activated PTSD)4-6 Yet, in other longitudinal studies of PTSD such as those 
conducted with war veterans,7 burn injury survivors,8 and 9/11,9 the findings have 
been inconsistent. For example, significant decreases in PTSD symptoms were 
found between two assessments 4 and 16 months following exposure to natural 
disaster, and individuals residing in Manhattan reported a decrease in PTSD 
symptoms following 9/11. In contrast, combat-related PTSD symptomatology 
remained constant or increased across assessments 1 month–2 years following 
return from the Persian Gulf War.  Also, the proportion of burn victims meeting PTSD 
diagnostic criteria increased at one year following injury.8 These mixed results are 
not surprising, given the different types of traumatic events studied coupled with the 
differences in the timing of the symptom assessments.   
Longitudinal assessments of cancer survivors that capture times of major life 
events (e.g., treatment cessation, job re-entry, recurrences, and changes in medical 
surveillance) would help determine the direction of causality between PTSD, PTG 
and QOL, and bolster the identification of risk factors to guide identification of 
patients and the selection and timing of phase-specific psychosocial treatments to 
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alleviate distress and enhance PTG.  In addition, from what is known of the risk 
factors identified in cancer-related longitudinal studies10-12 and in this dissertation 
study, there are opportunities to intervene early in the cancer experience, as many 
of these factors are modifiable (e.g., poor social support, negative appraisals). For 
example, in one of only three relevant studies identified in a MEDLINE search, 
breast cancer patients were assessed for PTSD 14 months after treatment 
completion and reassessed 12 months later.10 PTSD symptoms remained stable and 
did not diminish over time. In another study, breast cancer patients were assessed 
at 6 weeks and 1 year post-operatively and the frequency of PTSD symptoms was 
reduced at the one-year mark.11 In the third study, head and neck and lung cancer 
patients were assessed at 6 and 12 months post-diagnosis, and symptoms gradually 
subsided with no evidence of delayed-onset.12 Risk factors for persistent PTSD 
included less social support, more traumatic stressors prior to diagnosis, pre-morbid 
health conditions, and personality type of high emotional reactivity. Determining the 
optimal timing and administration of the applicable components of the treatment plan 
could accelerate not only the reduction of PTSD symptoms for cancer survivors, but 
enhance their overall QOL as well.  
Second, results from the SEM analyses in Chapter 2 demonstrated that PTSD 
symptoms and PTG help to explain the relationship between specific demographic, 
clinical, health status, and psychosocial variables and QOL. These findings give 
support to using PTSD as a diagnostic framework (and PTG, to a lesser extent) in 
understanding symptomatology in this population. However, given the absence of 
“good fit”, it is recommended that these findings be replicated with other measures 
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and in other cancer samples to improve their robustness.  With replication, our 
findings suggest that attention be given to reducing PTSD symptomatology and 
enhancing PTG in cancer survivors as a way to improve their QOL.  
Third, the impact of having active disease on self-reported QOL, regardless of 
the amount of time post-diagnosis, has important research design implications as 
described in Chapter 3. For example, psychosocial intervention design and 
development research might consider separate treatments based on disease status. 
In addition, further research is needed to understand how the distinguishing 
characteristics of NHL (alternating between periods of disease and remission) might 
lead to detriments in mental health. For example, our sample scored consistently 
lower on the SF-36 mental component summary measure than other cancer 
samples that are not characterized by these characteristics. As stated earlier, 
findings like these are relevant for cancer survivors in general, but particularly 
relevant for patients who are living with cancer as a chronic illness with alternating 
periods of active disease and remission.  
Implications for Practice 
Two areas of focus regarding psychosocial support and treatment for this population 
are described here. First, while interventions have been developed, tested and 
shown to reduce PTSD in trauma populations such as adolescent cancer13 and 
sexual assault,14 no specific therapies for PTSD in the cancer setting have been 
developed for adult survivors, according to the NCI15 and literature review. In other 
populations, such as rape survivors, cognitive behavioral therapy (CBT) and 
prolonged exposure (PE) have been shown to be an effective treatment for PTSD.14 
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However, cancer-related trauma has distinct features that could drive modification to 
existing therapies used to treat PTSD in other populations.  
Kangas, Henry & Bryant12 have identified several clinical issues resulting from 
the distinctive features of the cancer stressor. For example, a major issue relates to 
the ongoing nature of the trauma (e.g., treatments, medical surveillance, aversive 
side effects), which puts into question the timing of using PE in this population. If 
deemed appropriate, exposure activities should be conducted only after the 
demanding aspects of the medical treatment have ended. Furthermore, cognitive 
restructuring and anxiety management may be more beneficial than exposure in 
facilitating adaptive coping. The issues related to interventions with cancer survivors, 
combined with what is already known about the unique features of cancer-related 
PTSD and the knowledge gained from the dissertation study about the mediating 
effects of PTSD and PTG (see Chapter 2), suggest that psychosocial interventions 
be developed and tested to treat PTSD and enhance PTG in cancer survivors. 
Secondly, the risk factor analyses in Chapters 1 and 2 suggest that screening 
tools be developed and tested to identify those at risk for PTSD. Currently, the 
National Coalition of Cancer Networks Distress Management Screening Measure 
(DMSM) is being used in many oncology clinics to screen for general distress and 
impacts to daily functioning. However, this measure does not specifically assess for 
PTSD; therefore, this disorder may go undetected in a large number of survivors. 
Perhaps more disconcerting is that many survivors are followed up by their primary 
care physicians who may be unaware of the increased risk for PTSD in this 
population. Oncology social workers should consider discussing these issues with 
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their patients while they are still in active treatment or at treatment cessation before 
leaving the care of an oncology setting. Furthermore, findings from the QOL 
analyses in Chapter 3 comparing survivors with active disease to those that are 
disease-free suggest that health care professionals may want to pay close attention 
to survivors with active disease and screen for QOL-related problems as well. 
In summary, it was demonstrated in Chapter 1 that PTSD symptomatology is 
prevalent in this sample of cancer survivors. Given this identification, Chapter 2 
explored how PTSD and PTG mediate the relationship between various stressors 
(risk factors) and QOL. Finally, a more in-depth examination of QOL across three 
different survivorship statuses (active NHL, STS, LTS) was presented in Chapter 3, 
with findings of worse QOL for those who reported having active disease when 
compared to survivors who were in remission or cured. Overall, it is encouraging to 
consider that many of the psychosocial factors identified in this dissertation study 
that were significantly related to PTSD and worse QOL are potentially modifiable. 
Oncology social workers are in the unique position to identify those at risk and 
provide support and treatment to minimize PTSD symptomatology and enhance 
PTG, ultimately leading to improved QOL for this vulnerable, yet resilient, population. 
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